DIABETES AND OBESITY INDUCE TRANSCRIPTOMIC AND METABOLOMIC CHANGES ENHANCING PANCREATIC CANCER AGGRESSIVENESS by Velázquez Torres, Guermarie
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
5-2014
DIABETES AND OBESITY INDUCE
TRANSCRIPTOMIC AND METABOLOMIC
CHANGES ENHANCING PANCREATIC
CANCER AGGRESSIVENESS
Guermarie Velázquez Torres
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biochemistry Commons, Cancer Biology Commons, Endocrine System Diseases
Commons, and the Molecular Biology Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Velázquez Torres, Guermarie, "DIABETES AND OBESITY INDUCE TRANSCRIPTOMIC AND METABOLOMIC CHANGES
ENHANCING PANCREATIC CANCER AGGRESSIVENESS" (2014). UT GSBS Dissertations and Theses (Open Access). Paper 455.
DIABETES AND OBESITY INDUCE TRANSCRIPTOMIC AND METABOLOMIC 
CHANGES ENHANCING PANCREATIC CANCER AGGRESSIVENESS  
by 
Guermarie Velázquez Torres, M.S.  
 
 
APPROVED: 
 
 
______________________________ 
Mong-Hong Lee, Ph.D. 
Supervisory Professor 
 
 
______________________________ 
Sai-Ching J. Yeung, M.D., Ph.D. 
 
 
______________________________ 
Paul Chiao, Ph.D. 
 
 
______________________________ 
Huamin Wang, M.D. 
 
 
______________________________ 
Michele Forman, Ph.D. 
 
 
APPROVED: 
 
 
 
____________________________  
Dean, The University of Texas 
Graduate School of Biomedical Sciences at Houston 
 
DIABETES AND OBESITY INDUCE TRANSCRIPTOMIC AND METABOLOMIC 
CHANGES ENHANCING PANCREATIC CANCER AGGRESSIVENESS 
A 
DISSERTATION 
 
Presented to the Faculty of  
 
The University of Texas 
  
Health Science Center at Houston  
 
and 
 
The University of Texas 
M. D. Anderson Cancer Center 
Graduate School of Biomedical Sciences 
in Partial Fulfillment 
 
of the Requirements 
 
for the Degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
by  
Guermarie Velázquez Torres, B.S., M.S.  
Houston, Texas 
 
May 2014 
	   	   iii	  
Dedication 
 
I dedicate this work to my family.  My lovely husband Enrique, for supporting my 
decision to follow my dream and being a pillar in my life.  To my adorable 
daughters María Angélica, and Aurora Isabel who make my days shine.  Also, to 
my parents María V. Torres and Juan J. Velázquez for their lessons, always 
emphasizing the importance of getting a good education and for their 
unconditional support and love.  To my sister, Mili, my niece (Pilar A.), my 
nephew (Javier A.), and my family in law (Lola, Enrique, and Irma) for being 
present when I need them most. 
Finally, I want to dedicate this work to all the cancer patients that suffer from this 
devastating disease. 
 
 
 
 
 
  
	   	   iv	  
Acknowledgements 
This work would never been possible without the support and 
collaboration of many people.  
First, I want to thank Dr. Lee for accepting me into his laboratory and for 
supporting my career during these past years.  He has been a mentor in all the 
meaning of the word.  His lessons went beyond the laboratory practices to all the 
life aspects.  Thank you for always sharing your knowledge and for trusting me.  
In addition, I want to thanks Dr. Sai-Ching Jim Yeung, he also has been a mentor 
and I appreciate all his lessons from clinic to the bench, including the statistical 
analyses.   His clinical input, his expertise in endocrinology and cancer treatment 
care were essential for this research.  Both of them are role models to follow in 
life. 
Second, I want to thank the advisory, examination and supervisory 
committee members that guided me to complete this Ph.D. degree.  Dr. Michele 
Forman who in addition of being a member in my advisory and supervisory 
committees was my co-mentor in the Cancer Prevention training grant at The 
University of Texas M. D. Anderson Cancer Center  (R-25-T CA57730).  I really 
appreciate her guidance and enthusiasm.  Also, thank the Dr. Paul Chiao and Dr. 
Huamin Wang who served in all my committees, for their expertise in pancreatic 
cancer that were crucial for this research project.  Finally, I want to thank to Dr. 
Randy Legerski and Hui-Kuan Lin who served in my examination committee and 
	   	   v	  
the other members of the examination committee for their advise, critiques and 
rigorous examination.  
Third, I want to thank current and past members of Dr. Lee laboratory.  All 
of them left their prints in my life.  Particularly thank to Dr. Yin-Hsun Feng who 
started the research in pancreatic cancer at Dr. Lee’s laboratory.  To Dr. Enrique 
Fuentes-Mattei who collaborate in many aspects of this research including the 
mice surgery and bioinformatics analysis.  Thank to Jiun-Sheng Chen for his 
unconditional help, mainly with the animal experiments.  Especial thank to Dr. 
Chris Gully for his guidance and friendship when I started in the laboratory.  
Thank to Aiham Qdaisat for the scientific writing editing.  To all the laboratory 
members that collaborate and work together in the regular daily basis thank you.  
Many of them have become part of my family and I will always have you in my 
heart.  
Fourth, thank to the R-25-T CA57730Cancer Prevention training grant for 
their financial support and for made possible the metabolomic study.  Thank to 
Dr. Shine Chang, Dr. Carrie Cameron, and Dr. Robert M. Chamberlain for their 
dedication to promote cancer prevention research.   
Fifth, I want to thank Dr. Mien-Chie Hung for sharing his equipment and 
allow us to use his Xenogen IVIS 100 imaging system.  Dr. Dos Sarbassov, his 
laboratory members, Dr. Hui-Kuan Lin and Dr. Paul Chiao laboratory members 
for material support. Thank to the Department of Molecular and Cellular 
Oncology including the administrative personnel for always being so helpful and 
	   	   vi	  
resourceful.  Especial thank to Dr. Zhenbo Han and Su Zhang for their 
unconditional support. 
 Finally, I want to thank The University of Texas M. D. Anderson Cancer 
Center and The University of Texas Graduate School of Biomedical Sciences for 
the support to us, the students, and for promoting a higher education.  
 
 
	   	  vii	  
DIABETES AND OBESITY INDUCE TRANSCRIPTOMIC AND METABOLOMIC 
CHANGES ENHANCING PANCREATIC CANCER AGGRESSIVENESS 
Guermarie Velázquez-Torres, Ph.D. 
Supervisor Professor: Mong-Hong Lee, Ph.D. 
ABSTRACT 
Pancreatic cancer is one of the most aggressive types of cancer, with poor 
prognosis that lacks effective diagnostic markers and therapies.  It is expected 
that in 2014 the incidence and the mortality of pancreatic cancer in the United 
States will be 46,420 and 39,590 respectively.  Diabetes and obesity are 
modifiable risk factors associated with accelerated pancreatic carcinogenesis 
and tumor progression, but the biological mechanisms are not completely 
understood. The purpose of this study is to demonstrate direct evidence for the 
mechanisms mediating these epidemiologic phenomena. Our hypothesis is that 
obesity and diabetes mellitus type 2 (DM2) accelerate pancreatic cancer and that 
metformin treatment has a beneficial impact.  To determine the effect of glucose, 
insulin and adipocytes in pancreatic cancer proliferation we used conditioned 
media to mimic DM2 and obese conditions.  Also, we studied the effect of anti-
diabetic drugs, particularly metformin and rosiglitazone on pancreatic cancer.  
We established orthotopic/syngeneic mouse models to evaluate the effect of 
obesity (Ay/a) and diabetes (Leprdb/Leprdb) on pancreatic tumor growth and 
aggressiveness. Our results showed that both obesity and diabetes promote 
pancreatic tumor growth. Furthermore, enhanced tumor growth and 
aggressiveness (e.g., EMT) was explained by functional transcriptomic and 
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metabolomic changes in the mice with obesity and diabetes, namely via 
activation of the AKT/mTOR pathway. Metformin treatment decreased the 
obesity-induced and diabetes-induced AKT/mTOR pathway activation and tumor 
growth. Adipokine profile array showed an induced secretion of several 
adipokines in the obese and diabetic mice compared with lean mice. Our co-
culture system showed a direct impact of adipocytes on the growth of pancreatic 
cancer cells.  In conclusion, obesity and diabetes have adverse effects that 
promote pancreatic cancer progression by enhancing proliferation and 
aggressiveness via transcriptomic and metabolomic changes.  Adipocytes affect 
tumor microenvironment and cancer cell proliferation through the secretion of 
adipokines targeting cancer cells’ survival and proliferation. Our animal models 
provide strong evidence for the causal relationship between obesity, diabetes 
and accelerated pancreatic cancers. This study sheds a new insight of the effects 
of metformin and its potential as part of therapeutic interventions for pancreatic 
cancer in obese/diabetic patients. 
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Chapter 1. Introduction 
1.1 Pancreatic cancer 
Pancreatic cancer has an annual worldwide incidence of more than 300,000 
cases per year, it is among the top ten causes of cancer death worldwide (Li et 
al., 2012; Parkin et al., 2005), and remains fourth cancer-related cause of death 
in the United States (Maitra and Hruban, 2008).  Pancreatic cancer is one of the 
most aggressive malignancies with a five-year survival rate of approximately 5%.  
The pancreas is an organ that possesses endocrine and gastric or exocrine 
functions.  Its endocrine role includes the production of protein hormones such as 
insulin, glucagon, somatostatin, and pancreatic polypeptide that are secreted by 
the alpha, beta, delta and gamma cells of the Langerhans islets, respectively.  In 
addition, the pancreas produces pancreatic juice important for the digestion of 
carbohydrates, proteins, and lipids.  The types of malignancies that affect the 
pancreas mainly arise from exocrine component with pancreatic ductal 
adenocarcinoma (PDAC) the most common malignancy in the pancreas.      
 
1.1.1 Pancreatic cancer mouse models 
 PDX-1 and P48 are constitutively expressed transcription factors 
important for the pancreas development (Kawaguchi et al., 2002; Offield et al., 
1996), which promoters were used to conditionally express KRAS G12D 
transgene in the pancreas of mouse at embryonic stage (Hingorani et al., 2003).  
These mouse models express the pancreatic intraneoplasia (PanIN) stages 
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believed to be precursors of pancreatic cancer but very low percent of mice 
develop the pancreatic ductal adenocarcinoma.  In order to have the progression 
of pancreatic cancer, it requires additional mutations in tumor suppressor genes 
(e.g. TP53, P16/cdkn2A) (Perez-Mancera et al., 2012) that are known precursor 
lesions (Hruban et al., 2000) occurring in PDAC.  Recently the development of 
inducible mouse models provide the advantage of controlling the expression of 
mutant KRAS (Gidekel Friedlander et al., 2009; Ying et al., 2012).   
 In this research work, we studied pancreatic cancer in the context of 
obesity and diabetes. For this reason we used obese and DM2 
orthotopic/syngeneic mouse models using PancO2 mouse pancreatic cell line 
(Corbett et al., 1984).  This cell line was previously shown to be resistant to 
almost all of the chemotherapeutic agents tested (Corbett et al., 1984) 
representing an excellent model to study pancreatic cancer. 
 
1.2 Diabetes mellitus type 2 
Many epidemiological studies suggest the important role of diabetes mellitus 
type 2 (DM2) in carcinogenesis (Coughlin et al., 2004; Muti et al., 2002; Nilsen 
and Vatten, 2001; Richardson and Pollack, 2005; Verlato et al., 2003; Yamagata 
et al., 2005), cancer survival (van de Poll-Franse et al., 2007), and as a 
significant risk factor for pancreatic cancer (Ansary-Moghaddam et al., 2006; Lu 
et al., 2006).  Moreover, pancreatic cancer is associated with DM2 (Ben et al., 
2011; Everhart and Wright, 1995; Fisher, 2001; Kuriki et al., 2007; Lu et al., 
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2006; Stolzenberg-Solomon et al., 2005) and approximately 80% of pancreatic 
cancer patients have DM2 (Permert et al., 1993).  
DM2 has been associated with pancreatic cancer, but there is no clear 
answer of which one comes first.   There are two possibilities: pancreatic cancer 
promotes DM2 or DM2 leads to pancreatic cancer carcinogenesis (Wang et al., 
2003).  Literature support both hypotheses (Wang et al., 2003) and it is possible 
that they are not exclusive between them.  If DM2 results from pancreatic cancer, 
it is possible for DM2 to have a positive feedback in promoting carcinogenesis 
and cancer progression.  On the other hand if diabetes comes first, then 
pancreatic cancer can be viewed as an aggravation of DM2 (Everhart and 
Wright, 1995).  However, more studies are needed to confirm diabetes as a risk 
factor for pancreatic cancer (Pezzilli and Pagano, 2013).  Therefore, optimal 
treatment of DM2 may play a major role in the primary prevention of pancreatic 
cancer in diabetics.  
Different drugs are used for diabetes treatment and these drugs have diverse 
mechanisms of action and targets.  The pharmacotherapy for diabetes includes: 
insulin/insulin analogs, sulfunylureas, meglitinides, alpha glucosidase inhibitors, 
thiazolidinediones, biguanides, incretin mimetics, DDP-4 inhibitors and amylin 
analogs.  Treatments of DM2 have different effects on insulin and IGF-1 signaling 
and some of these treatments might be useful to prevent pancreatic cancer.  In 
this research study we focused on the study of the biguanide drug, metformin but 
we also used other drugs as rosiglitazone/pioglitazone and excenatide.  As it has 
been previously reported, metformin activates AMPK (Jackson et al., 2001).  
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Metformin improves glycemic control by decreasing intestinal absorption of 
glucose and improving insulin sensitivity in muscle and liver tissue (Ota et al., 
2009).  Another drug of interest are the thiazolidinediones 
rosiglitazone/pioglitazone known to activate PPAR-γ (Teresi et al., 2006).  
Rosiglitazone reduced lipid availability, improves insulin action and gluco-
regulation (Oakes, M.D. 1994).  Excenatide is a glucagon like peptide-1 receptor 
agonist, an incretin mimetic (Pi-Sunyer, 2008). 
 
1.2.1 Diabetes mellitus type 2 mouse model 
For the purpose of this study we used the diabetes mouse model Leprdb/db.  
The leptin receptor gene in this mouse model contains a point mutation that 
results in a stop codon that shortens the intracellular domain and abolishes its 
signaling capacity (Koenig and Cerami, 1975).  In order to express the disease it 
is necessary to have homozygous Leprdb/Leprdb (db/db), which is a common 
mouse model of DM2.  
The expected median survival of the homozygous db/db mice is 13.3 months 
(Barouch et al., 2006).  At the age of two weeks old db/db mice start to show high 
levels of insulin and at 5 weeks old these mice start to show high glucose levels 
(Koenig and Cerami, 1975).  Around the age of 3 to 4 weeks, these mice become 
obese but with normal glucose levels (Koenig and Cerami, 1975).  Then at the 
age of 7 to 8 weeks of age these mice are considered obese, with high glucose, 
insulin, and glucagon.  It is not until 12 – 20 weeks of age when the insulin levels 
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in these mice decrease toward normal (Roesler et al., 1990), similar to what 
occur in diabetic patients. 
 
1.3 Obesity  
The World Health Organization (WHO) defines obesity as “abnormal or 
excessive fat accumulation that presents a risk to health”. The body mass index 
(kg/m2) is used to classify individuals as underweight, normal, overweight, and 
obese (Table 1.3).  Obesity is an increasing health issue that is an ongoing 
pandemic problem affecting millions of people all over the World (James, 2008).  
Obesity is also linked to DM2 (Hossain et al., 2007).  Currently, more than the 
35% of both adult men and women are obese in the US (Flegal et al., 2012).  
Unfortunately, obesity is a modifiable risk factor associated with accelerated 
pancreatic cancer progression and shorter survival (Ansary-Moghaddam et al., 
2006) and also related to other cancer types (Reeves et al., 2007). 
Epidemiological studies strongly suggest a correlation between obesity and 
pancreatic cancer, but little is known about the possible biological mechanisms 
by which obesity promotes the pancreatic tumor growth, aggressive progression 
and drug resistance. The promotion of pancreatic cancer by obesity may be 
explained by hyperglycemia and deregulated adipokines secretion by adipocytes.  
However, an important emerging cancer hallmark is the reprogramming of cancer 
cells metabolic profile for survival, proliferation, invasion, metastasis and drug 
resistance (Hanahan and Weinberg, 2011).  Some research groups have 
described the involvement of the PI3K/AKT signaling pathway on pancreatic 
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cancer cell proliferation, motility and migration (Perugini et al., 2000; Teranishi et 
al., 2009).  Thus, in order to further understand the underlying mechanisms of 
obesity-induced pancreatic cancer, we need to determine the signaling pathways 
related to these effects. 
One of the most recent FDA approved drugs for obesity is Orlistat.  Orlistat 
inhibit GI lipases and block or prevent the absorption of about 30% of dietary fat 
(Pi-Sunyer F.X. 2008).  For this study we tested orlistat effect in cell proliferation 
and glucose uptake. 
 
Table 1.3: Adult Body Mass Index Classification 
Body Mass Index classification 
Underweight <18.5 
Normal Range 18.5-24.9 
Overweight:  ≥25.0 
     Pre-obese 25.0-29.9 
Obese: ≥ 30.0 
     Obese Class I 30-34.9 
     Obese Class II 35.0-39.9 
     Obese Class III ≥40 
 
Adapted from World Health Organization: 
(http://www.who.int/dietphysicalactivity/childhood_what/en/) 
 
1.3.1 Obese mouse model 
Among several mouse models for obesity, the agouti gene mutants have 
been extensively studied (Chua, 1997; Robinson et al., 2000; Walkley et al., 
1978).  In mammals, the agouti gene (a) encodes a paracrine protein factor (131-
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amino-acid protein), which antagonize melanocortin-1 receptor (Mc1r), α-
melanocyte-stimulating hormone (α-MSH) receptor, melanocortin-3 receptor 
(Mc3r) and melanocortin-4 receptor (Mc4r) (Eberle et al., 2001; Kiefer et al., 
1997; Lu et al., 1994; Ollmann et al., 1998; Yen et al., 1994). The agouti gene 
mutants (e.g., lethal yellow Ay and viable yellow Avy) are dominant regulatory 
mutations that cause the wild-type agouti protein to be produced abnormally 
throughout all the body due to the control of the Raly promoter.  This over-
expression decreases the melanocortin signals inducing hyperphagia and obesity 
(Hustad et al., 1995; Wisse et al., 2003).  Heterozygotes (Ay/a) mice have ectopic 
expression of agouti protein promoting pleiotropic phenotypes that include yellow 
fur, hyperphagia (excessive hunger or increased appetite), and obesity with 
increased adipose tissue mass accounting for 30-35% of total body weight after 
the first few months.  The Ay/a mice yellow fur phenotype is due to the inhibition 
of α-MSH / adenylyl cyclase-induced eumelanin (brown-black pigment) synthesis 
in hair follicular melanocytes by agouti protein leaving on the production of 
phaeomelanin (yellow-red pigment) (Lu et al., 1994). Disruption of the 
melanocortin signaling in the brain by the agouti protein is the principal cause of 
hyperphagia and subsequently to obesity (Wisse et al., 2003). The Ay/a mouse 
model recapitulates the human obesity phenotype and obesity-induced endocrine 
profile (Fuentes-Mattei et al., 2014 In Press). Thus, heterozygous (Ay/a) are a 
suitable obese mouse model to study the effect of obesity on pancreatic tumor 	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1.4 Cancer metabolism 
One of the emerging hallmarks of cancer cells is the changes in cell 
metabolism (Hanahan and Weinberg, 2011) where mitochondrial oxidative 
phosphorylation is switched to glycolysis.  High expression of glucose transporter 
1 (GLUT1) occurs in cancer cells (Reske et al., 1997), to internalize more 
glucose used to compensate the energy production and high rate of glycolysis.  
Lactate formation results from these metabolic changes (Ramanathan et al., 
2005).  In addition, there are changes in gene expression as it occurs with the 
up-regulation of transcription factors c-MYC and hypoxia inducible factor-1 (HIF-
1) (Altenberg and Greulich, 2004; Dang, 1999; Denko et al., 2003; Robey et al., 
2005) or down-regulation of p53 protein (Bensaad et al., 2006; Garber, 2006). 
In pancreatic cancer, common genetic alterations include activation of the K-
Ras (~90%) and loss of function of p53 tumor suppressor gene (50% to 75%) 
(Hruban et al., 1999), both of which contribute to the glycolytic phenotype. 
Expression of glycolytic enzymes is increased in pancreatic cancer compared 
with paired noncancerous tissue (Mikuriya et al., 2007) and HIF-1α may mediate 
trophic effects of insulin on pancreatic cancer (Wang et al., 2007). In the context 
of DM2, activation of the protein kinase B (AKT)/ mammalian target of rapamycin 
(mTOR)/HIF-1a pathway by insulin and/or IGF-1 (Scheid and Woodgett, 2001) 
may also be driving the glycolytic phenotype to promote the survival of cancer 
cells. Cancer cells use glucose to generate energy and phospho-metabolites to 
drive cell division, growth, repair of DNA damage and drug detoxification 
(Mazurek et al., 1997).  
	   	   9	  
There are several processes that may be promoting pancreatic cancer under 
obese and DM2 conditions.  Some of these factors are: high glucose, high 
insulin, and hyper-activity of insulin-like-growth-factor-1 (IGF-1) (Li et al., 2009). 
Different DM2 treatments have diverse mechanisms of action that will affect the 
pancreatic cancer carcinogenesis.  
Specific types of treatments for DM2 may have different impact on pancreatic 
cancer based on their mechanisms of action, thereby having different outcomes 
in terms of pancreatic cancer carcinogenesis and/or progression.  
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1.5 Rationale and hypothesis 
1.5.1 Significance and rationale 
Pancreatic cancer is one of the most aggressive, with poor prognosis, lacking 
effective diagnostic markers and therapies.  Diabetes and obesity are modifiable 
risk factors associated with accelerated pancreatic carcinogenesis and tumor 
progression. However, the biological mechanisms by which diabetes and obesity 
promote pancreatic cancer are not completely understood.  The purpose of this 
study is to demonstrate direct evidence for the mechanisms mediating these 
epidemiologic phenomena.  This research work shed a new insight of the 
biological mechanism involved in the effects of obesity and diabetes on 
pancreatic cancer aggressiveness.  This research work also shed a new insight 
on the effects of metformin and its potential as part of therapeutic interventions 
for pancreatic cancer in obese patients. 
 
1.5.2 Hypothesis 
Obesity and DM2 accelerate pancreatic cancer and metformin treatment has 
beneficial impact on primary prevention of pancreatic cancer. 
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Chapter 2. Materials and methods 
2.1 Chemical and reagents 
Metformin (Enzo Life Sciences, Farmingdale, NY), was prepared at 400 mM 
in distilled, deionized autoclaved water and filtered for sterile condition.  Dilutions 
were prepared in water or media depending on the experiment. Rosiglitazone 
(Cayman Chemicals, Ann Arbor, MI) stock was prepared in Dimethyl sulfoxide 
(DMSO) (Fisher, Pittsburg, PA) at a concentration of 100mM for each 
experiment. D-Glucose, insulin, and methylthiazolydiphenyl-tetrazolium bromide 
(MTT) were obtained from Sigma (St. Louis, MO). 
 
2.2 Cell culture 
2.2.1 Pancreatic cancer cells 
MIA PaCa-2 and Panc-1, human pancreatic ductal adenocarcinoma cell lines 
were obtained from American Type Culture Collection (ATCC; Manassas, VA).  
PancO2, pancreatic ductal adenocarcinoma mouse cell line, was kindly provided 
by Dr. Paul Chiao.  This cell line was established from C57BL/6 mice in 1984 
(Corbett et al., 1984). Cells were maintained in DMEM/F12 (Sigma, St. Louis, 
MO) supplemented with 10% fetal bovine serum (FBS) (Gemini, West 
Sacramento, CA) and 1% antibiotic/antimycotic solution (10,000 IU Penicillin (per 
mL), 10,000ug/mL Streptomycin 25ug/mL Amphotericin) (Corning Life Sciences 
Mediatech Inc, Manassas, VA). Cells were kept at 37oC in humid condition with 
5% CO2.  
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2.2.2 Differentiation of 3T3-L1 and co-culture conditions 
Pre-adipocyte mouse fibroblast, 3T3-L1 were obtained from ATCC 
(Manassas, VA) and kept in DMEM supplemented with 10% bovine calf serum.  
Differentiated adipocytes were obtained by culture 3T3-L1 with differentiation 
media containing 115 mg/mL methyliobutylxanthine, 10 µg/mL insulin, and 5 µM 
dexamethasone for 48 hours.  After 48 hours cells were culture with 10 µg/mL 
insulin for 48 hours.  Then, for 96 hours differentiated 3T3-L1 adipocyte cells 
were kept in high glucose DMEM, 10% FBS to complete differentiation.  The 
3T3-L1 fibroblast cells were used only for up to 10 passages before 
differentiation.  
 Transwell-clear permeable inserts of 0.4 µm pores (Corning Life Sciences 
Mediatech Inc, Manassas, VA) were used to determine the effect of adipocytes 
on pancreatic cancer migration. Adipocytes from 3T3-L1 were grown in 6-well 
transwell plates and 25,000 PancO2 cells were seeded in the transwell Boyden 
chamber (top). Cells that migrate through the membrane were determined by 
crystal violet staining.  PancO2 cells were co-cultured with matured adipocytes 
for 72 hours. The cell number of PancO2 and adipocytes were determined by 
counter coulter and PancO2 cell number was normalized to the number of 
adipocytes. The cell viability was determined using Trypan blue (Sigma, Saint 
Louis, MO) exclusion assay. Each treatment/condition was made in at least three 
separate independent cell population (n=3) to allow for statistical evaluation. 
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2.2.3 Media to mimic DM2 and obese conditions 
 In order to reproduce the glucose and insulin conditions found in diabetes 
and obese patient, MIA PaCa-2 cells were cultured in different media to perform 
MTT assays (Table 2.2.3).  Normal condition media was prepared by adding 
normal serum levels of glucose (100 mg/dL) and insulin (0.0005 mg/L).  Diabetes 
media contained high glucose and high insulin (400 mg/dL and 5 mg/L 
respectively).  Obese media had normal glucose (100 mg/dL), high insulin (5 
mg/L) and leptin (6.24 nM). 
 
 
Table 2.2.3: Conditioned media to mimic diabetes type 2 (DM2) and obese 
situation.  
Condition Glucose (mg/dL) 
Insulin 
(mg/L) Leptin (nM) 
Normal  100 0.0005 --- 
Diabetes Mellitus Type 2 
(DM2) 400 5 --- 
Obese 100 5 6.24 
DM2/Obese 400 5 6.24 
 
 
2.3 Protein extractions and quantification 
2.3.1 Cell harvesting for protein extraction 
Cells were culture in 10 cm dishes or 6-wells, and treated for 24-72 hours as 
indicated in the experiments. In order to collect all the cells, including those that 
were loosely attached, cells were scrapped by using a cell lifter (Corning Life 
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Sciences Inc, Manassas, VA) while still in the media.  Then, cells were washed 
twice with Phosphate buffer saline (PBS) and centrifuged at 1,400 rpm to remove 
media and cell wastes.  For the second wash cells were transferred to 
microtubes and centrifuge in the microcentrifuge (Eppendorf, Hauppauge, NY).  
Cell pellet were subjected to protein extraction or freeze at -80oC for further 
processing.  For protein extraction, cell pellets were lysed with 100-500 µL of 
lysis buffer: 20 mM Tris-HCl pH 8.0 (Fisher, Pittsburg, PA), 100 mM NaCl 
(Fisher, Pittsburg, PA), 1mM EDTA (Fisher, Pittsburg, PA), 0.1% Nonidet P-40 
(USB Corp. Santa Clara, CA), 0.1% Triton X-100 (Sigma, Saint Louis, MO).  The 
following phosphatases and proteinases inhibitors were added to the lysis buffer 
to prevent protein dephosphorylation and protein degradation: 1 mM sodium 
orthovanadate, 1 mM sodium fluoride, 0.1 mg/ml Pepstatin A, 1 mM 
phenylmethylsulfonyl fluoride, and a mixed of protease inhibitor cocktail (0.2 
mg/mL aprotinin, 0.1 mg/mL antipain, 2 mg/mL soybean trypsin inhibitor, and 1 
mg/mL leupeptin) (Sigma, Saint Louis, MO). Cells were incubated on ice with the 
lysis buffer for 20 minutes and sonicated for 10 seconds to extract the cell 
proteins.  Centrifuged at 14,000 rpm in a refrigerated microcentrifuge during 20 
minutes to precipitate cell debris. Protein extracts were collected and quantitated 
for further analysis.  
 
2.3.2 Tissue preparation for protein extraction 
Snap frozen tumors were placed on dry ice, portions of the tumors were cut 
and weighed to lyse.  Tumors sections were placed into 5 mL tubes while kept on 
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ice. To extract the proteins ice-cold lysis buffer (see section 2.3.1) was added to 
each tumor in a ratio of 1 mL for each 40 mg of tumor. Tumors were 
homogenized by using an electric homogenizer for 8 seconds. Homogenizer 
probe was washed twice in between each sample.  Tumors were incubated in 
lysis buffer 10 minutes in ice and sonicated for 10 seconds. Then, cell lysates 
were transferred to microtubes and centrifuged at 14,000 rpm at 4oC in a 
microcentrifuge (Eppendorf, Hauppauge, NY) to precipitate the cell debris.  
Supernatant fraction containing cell proteins were transferred to new microtube 
and protein concentrations were determined. 
 
2.3.3 Determining protein concentration 
Protein concentrations were determined using the Protein Assay Dye 
Reagent (Bio-Rad, Hercules, CA).  A standard curve using Albumin Bovine 
Serum (BSA) (Sigma, Saint Louis, MO) was used to calculate the concentration 
of each sample.  The optical density was read on Powerwave XS microplate 
spectrophotometer (Biotek, Winooski, VT).  Samples were prepared to have 
equal amount of protein per volume (e.g. 1 µg/µL).  Samples used for Western 
Blot analysis were prepared by adding 5x sample buffer (100 mL: 3.78g Tris 
base, 5.0g SDS, 25g sucrose, 0.04 g bromophenol blue, pH6.8) containing 5% of 
2-mercaptoethanol (Sigma, Saint Louis, MO) and boil for 5 minutes to denature 
the proteins and break disulfide bonds before loading into the polyacrylamide gel.  
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2.3.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
 Polyacrylamide gels were prepared by using 30% Acrylamide/bis-acrylamide 
solution (37.5:1 ratio) (Bio-Rad), gels could be stored at 4oC for up to one week 
prior to loading the samples.  The gels used for these experiments were between 
8% to12% depending on the molecular weight of the protein to be detected.  
After gel electrophoresis samples were wet transferred (transfer buffer: 25 mM 
Tris base, 192mM Glycine, pH 8.2-8.4 with 20% methanol) to a polyvinylidine 
fluoride (PVDF) (Millipore, Billerica, MA).  Membranes were stained with 
Ponceau S (Sigma) by incubating 5 minutes in a 0.1% Ponceau in 1% acetic acid 
solution to detect protein transference. Membranes were subjected to Western 
Blot analysis.  
 
2.3.5 Western Blot analysis 
PVDF membranes, obtained from the transference, were blocked according 
to the antibodies of interest.  For total protein detection, we used 5% non-fat milk 
in Tris-Buffer saline (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween-
20 (Fisher) (TBS-T).  Membranes designed for detection of phosphorylated 
proteins were blocked with 5% BSA in TBS-T.  Membranes blocking were 
performed 1 hour at room temperature.  Blocking solution was discard and 
membranes were briefly washed with TBS-T. Incubation with primary antibodies 
was at 4oC overnight.  After primary antibody incubation membranes were 
washed three times with TBS-T for 10-15 minutes each.  Secondary antibody, 
conjugated to horseradish peroxidase, incubation was performed at room 
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temperature for 1 hour.  Then, membranes were washed with TBS-T three times 
for 10-15 minutes each, to remove any remaining antibody.  For protein 
detection, membranes were incubated with the Millipore Luminata Crescendo 
chemiluminiscence substrate (Millipore) and detected by photographic film 
(Denville Scientific, South Plainfield, NJ).   
See Table 2.3.5 for antibody information. 
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Table 2.3.5: Antibody List 
Name Source Company Catalog Number 
Actin Rabbit Sigma A2066 
Annexin V-FITC Mouse BD Biosciences 556419 
Anti-poly (ADP ribose) 
polymerase (PARP) Mouse 
BD 
Biosciences 551024 
AMPK Rabbit  Cell Signaling 2532 
mTOR Rabbit Novus Biologicals 28130002 
pAMPK (Thr172) Rabbit Cell Signaling 2535 
p70S6 Kinase Rabbit Cell Signaling 9202 
Phospho-p70S6 Kinase 
(Thr389) Mouse Cell Signaling 9206 
Tubulin Mouse Sigma T-5168 
PTEN Rabbit Cell Signaling 9552 
AKT Rabbit Cell Signaling 9272 
Phospho-AKT (Ser473) Rabbit Cell Signaling 9271 
Bcl-2 BD Bioscience 
BD 
Biosciences 610538 
S6 ribosomal protein Rabbit Cell Signaling 2217 
Phospho-S6 Ribosomal 
Protein (Ser235/236) Rabbit Cell Signaling 4856 
4E-BP1 Rabbit Cell Signaling 9452 
Phospho-4E-BP1 
(Ser65) Rabbit Cell Signaling 9456 
Phospho-mTOR 
(Ser2448) Rabbit Cell Signaling 2971 
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2.4 Flow cytometry analysis 
 2.4.1 Apoptosis analysis 
Cells were cultured in 6 well-plates and treated with the specified treatment 
conditions.  At the time of collecting the cells for apoptosis assay first we 
collected the media, containing loosely attached cells, followed by trypsinization 
and collection of attached cells. Together, cells were centrifuged at 1,400 rpm for 
5 minutes and washed twice with PBS. Cells were resuspended in 500 µL of 1x 
binding buffer, prepared fresh from the 10x Binding buffer (0.1 M HEPES, pH 7.4; 
1.4 M NaCl; 25 mM CaCl 2) (Axxora Platform) and Annexin V (BD Biosciences, 
San Jose, CA).  Control cells without Annexin V were used on each experiment. 
Incubation with Annexin V was performed at room temperature for 15 minutes 
and samples were protected from light. Then, cells were washed twice with 1x 
binding buffer.  Propidium iodide (10 µL of the 50 µg/mL dilution) (Sigma) with 
RNAse A (500 mg/ml, Roche) was added before doing the flow cytometry 
analysis using the BD FACS Canto II (BD Biosciences, San Jose, CA).  Cells 
were divided between healthy population, necrotic cells, early apoptosis, and late 
apoptosis.  
 
 2.4.2 PI staining 
Cells were cultured in 6-wells plates.  Appropriate treatments were applied 
for 24-48 hours.  Cells were washed with PBS and scrapped to detach and 
transferred to a tube.  After centrifugation, 500 µL of hypotonic propidium iodide 
buffer (0.1% Sodium citrate (Sigma), 0.1% Triton X-100, 50 µg/mL Propidium 
iodide, 0.5 mg/mL RNAse) were added to each sample and incubated for 30 
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minutes protected from the light.  Samples were place on ice and immediately 
analyzed for cell cycle using a FACS Canto II flow cytometer (BD Biosciences, 
San Diego, CA). 
 
 2.4.3 Cell sorting 
Cells infected with FG12 vector containing GFP were expanded for cell 
sorting.  Cells were washed with PBS and trypsinized.  The number of cells was 
determined using the hemacytometer.  After centrifugation, 10-20 million cells 
were re-suspended in 1 mL of media, transferred to a Falcon tube with a cell 
strainer cap (Corning Inc, Corning, NY) to separate into single cells.  Cells were 
sorted by GFP signal using the FACS Aria II (BD Biosciences, San Jose, CA).  
Parental cells not infected with the Luciferase plasmid were used as control 
(Figure 2.4.3).  Cells were collected into media and eventually plated in to cell 
culture dish.  
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Figure 2.4.3: Green fluorescent protein (GFP) PancO2 cell sorting. PancO2 
cells infected with lentivirus Luc-FG12 were sorted for GFP positive cells.  Non-
infected PancO2 cells (left panel) were used as control. The Luc-FG12 
PancO2cells positive for GFP (right panel) were collected and plated to expand 
for orthotopic syngeneic mice experiments. 
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2.5 Time-lapse microscopy 
 For each experiments cells were treated as described.  Cells were plated 
to form a monolayer and kept in the incubator overnight. Cell wounds were 
performed inside the biosafety cabinet by using a sterile tip.  Then, culture media 
was replace for the treatment media containing metformin (5 mM) or 
rosiglitazone (100 µM).  The microscope (Zeiss, Oberkochen, Germany) was set 
to keep a temperature of 37oC and 5% CO2 in a humid environment.  Axio Vision 
Rel 4.6 software was used to set the parameters for the image capture. Several 
images were taken from each treatment. For each well three different areas were 
captured every 30 minutes for over 36 hours time period.  A minimum of 3 
biological replicas for each condition was performed.  Wound gap was analyzed 
using Image J (software from National Institute of Health, MA). 
  
2.6 Proliferation assay 
 2.6.1 Cell counting 
In order to determine the treatment effect on cell proliferation cells were 
counted using a hemacytometer or using Z1 Coulter counter (Beckman Coulter, 
Fullerton, CA).  Cells were cultured in 6-well plates and treated for 24 hours after 
plating.  Treatments were performed for 24 to 48 hours in triplicates.  Then, cells 
were tripsinized and counted.  Average cell numbers were plotted 
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2.6.2 MTT assay 
For proliferation assay cells were plated to obtain a confluence of 20% 24 
hours after plating (between 2,500 to 10,000 cells depending on the cell type) in 
96-well plates.  Then, media was carefully aspirated and 200 µL of treatment 
media (Table 2.2.3) were added.  After 48 hours incubation 20 µL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) solution 
were added, MTT assay (Feng et al., 2011).  After 2 to 4 hours incubation, media 
was aspirated and 200 µL of DMSO were added to solubilize the dye formed 
from the MTT reaction. Plates were shake in a rotary mixer and the 570 nm 
optical densitometry was measured in a plate spectrophotometer MRX revolution 
(Dynex Technologies, Chantilly, VA) or Powerwave XS microplate 
spectrophotometer (Biotek, Winooski, VT). Each condition had at least 4 replicas.  
Statiscal analyses were performed using Sigma plot XXII software (Systat Inc., 
San Jose, CA).  To determine the Inhibitory concentration (IC50) sigmoidal curve 
fitting was used and one-way anova was used for comparison between multiple 
groups. 
 
2.7 Extracellular acidification rate (ECAR) and oxygen consumption rate 
(OCR) levels using seahorse 
Pancreatic cancer cells were cultured with their respectively treatments or 
in co-culture with adipocytes.  For treatments, cells were plated in the XF24 
microplate (Seahorse, North Billerica, MA) and treated 24 hours before assay.  
Cells co-cultured with adipocytes were tripsinized and plated in the XF24 
microplate (Seahorse, North Billerica, MA) 8 hours before the assay to have a 
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monolayer (20,000 cells/well).  Low sodium bicarbonate assay Medium pH 7.4 
(Seahorse, North Billerica, MA), was prepared the night before running the assay 
by adding 1 mM sodium pyruvate, 1 mM glutamine, 25 mM D-glucose and placed 
at 37oC. Cartridge was re-hydrated with assay buffer overnight and incubated in 
a hypoxic incubator. Culture media was replaced for above mentioned low 
sodium bicarbonate assay medium pH 7.4 and equilibrated 1 hour in a hypoxic 
incubator at 37oC. 
A series of mitochondrial inhibitors were used to determine the glycolysis 
and mitochondrial respiration capacities of the cells after the treatments.  In order 
to inhibit the ATP synthase, 10 mM oligomycin (Sigma, Saint Louis, MO) were 
added to determine mitochondrial independent oxygen consumption.  To 
determine the maximal respiration, 10 mM hydrophobic acid carbonylcyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma, Saint Louis, MO), a proton 
ionophore was used.  Finally, a combination of 10 mM Rotenone (Sigma, Saint 
Louis, MO) and Antinamycin A (Sigma, Saint Louis, MO), mitochondrial electron 
transport inhibitors at complex I and III respectively, were used to determine the 
spare respiratory capacity.  Inhibitors were sequentially added to establish the 
ECAR and OCR.  Results were analyzed using Seahorse XF software 
(Seahorse, North Billerica, MA).  To normalize the results protein concentration 
was determined.  
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2.8 Glucose uptake 
The fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol- 4-
yl)amino)-2-deoxyglucose (2-NBDG),  was used to determine its uptake into the 
cells. Glucose free medium (Life Science Technology, Grand Island, NY) 
containing 120 µM 2-NBDG and 10% FBS was used to replace the media the 
day of the experiments.  Images were taken with a fluorescent inverted 
microscope (Nikon, Melville, NY) before media replacement, 15 minutes, 30 
minutes, 1 hour, and 2 hours after 2-NBDG media was added.  Fluorescent 
microscopy images were taken using 488-wavelength filter.  At the same time 
points flow cytometry analysis to determine the percent of positive fluorescent 
cells was performed, BD FACS Canto II (BD Biosciences, San Jose, CA).  
 
2.9 Lentiviral infection  
 FG12 plasmid and virus packaging were kindly provided by Dr. Paul 
Chiao. The FG12 plasmid was originally developed by Qin, X. F. et al. (Qin et al., 
2003) and it was modified to contain the luciferase promoter by Dr. Paul Chiao’s 
laboratory (Figure 2.9) here on called Luc-FG12.  Packaging vectors contain the 
expression plasmid lentiviral vector vesicular stomatitis virus (VSV)- G, and two 
HIV lentiviral packaging constructs pRSVREV and pMDLg/pRRE (Qin et al., 
2003).  To produce the virus 293T cells were transfected with 10 µg of each 
plasmid Luc-FG12 (containing GFP and luciferase), VSV- G, pRSVREV, and 
pMDLg/pRRE using liposomes (Zou et al., 2002).  Virus was collected 48 and 72 
hours after transfection of 293T cells.  Culture media from 293T cells was 
collected and filtered by a 45 µm syringe filter.  Then, 2 mL of fresh media and 8 
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µg/mL of polybrene were added to the media containing the virus.  Virus 
containing media was used to infect PancO2 cells, which were plated the day of 
the transfection into 6-well plates.  After adding 2 mL of virus containing media to 
each well cell plate was centrifuged at 1,800 rpm for 45 minutes.  Plates were 
incubated at 37oC and 5% CO2.  Infection was repeated at 48 and 72 hours.  To 
confirm transfection, cells could be observed under the microscope to detect the 
GFP.  To select only those infected cells positive for GFP, flow cytometry 
analysis cell sorting (See section 2.4.3 Cell Sorting).  Sorted cells were expanded 
and used for mice experiments.  
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Figure 2.9: Lentiviral vector Luc-FG12.  Relevant portions are shown in the 
figure above.  The vector contains the cytomegalovirus (CMV) promoter, the HIV 
Flap element, the insertion site of Luciferase, and the EGFP sites.  FG12 vector 
(Qin et al., 2003) was developed from the FUGW (Lois et al., 2002) vector that 
came from the human immunodeficiency virus-1 (HIV) lentiviral vector (Miyoshi et 
al., 1998).  
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2.10 Mouse Models 
2.10.1 Nude Mice Xenograft 
Nude mice were obtained from the Department of Experimental Radiation 
Oncology at The University of Texas M. D. Anderson Cancer Center (Houston, 
TX).  Mice were maintained in barrier facility in compliance with all animal care 
and use guidelines.  All animal experiments were performed in accordance to M. 
D. Anderson Institutional Animal Care and Use Committee (IACUC) and 
approved by the American Association for Laboratory Animal Science (AALAS).  
MIA PaCa-2 cells were injected in the flank of mice at a concentration of 
500,000 cells in 200 µL of PBS.  Metformin (1g/Kg/day) and rosiglitazone (1.5 
mg/Kg/day) were provided in drinking water.  Tumor growth were monitored 
measuring with a caliper and tumor volume was estimated by: Length x Width2 /2 
(Osborne et al., 1985).  Mice were sacrificed before tumors reach the 1.5 cm 
mean diameter.  Tumors were collected and weighed.  Tumors were collected for 
protein extraction and immunohistochemistry (IHC) analysis.  
 
2.10.2 Obese and Diabetic Mouse Models   
Different strains of C57 B6 background mice, obtained from Jackson 
laboratories (Bar Harbor, MN), were used to mimic obese and diabetic mouse 
model conditions.  Agouti gene mutant mice, Ay/a obese mouse model B6.Cg-
Ay/J stock: 000021 (Bar Harbor, MN).  Leptin receptor heterozygous mutant 
mouse model +/Leprdb mice strain: B6.Cg-m +/+ Leprdb/J; stock: 000697, was 
obtained from Jackson Laboratories (Bar Harbor, MN).  C57 BL/6J stock:000664 
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wild type mice were used as breeders.  Breeding pairs were obtained from 
Jackson Laboratories and mice were bred in the institution animal facility 
following the regulations.  Obese mice Ay/a were crossed with C57BL/6J wild 
type mice to obtain Ay/a mice, homozygous Ay mice are lethal.  The yellow fur 
identified Ay/a mice.  Heterozygous leptin receptor mutant mice +/Leprdb were 
crossed with itself to obtain Leprdb/Leprdb mice that are diabetic/obese mouse 
model.  To identify leptin receptor mutant mice, mouse genotyping were 
performed.  Wild type littermates were used as experimental controls.  These 
mice were used for the Orthotopic syngeneic mouse experiments.  All animal 
experiments were performed in accordance to M. D. Anderson Institutional 
Animal Care and Use Committee and approved by the American Association for 
Laboratory Animal Science (AALAS).  
 
2.10.3 Mouse Genotyping 
Leptin receptor db mutant mice were identified by genotyping.  Briefly, 
mice tails were clipped (0.5 cm) after 15 days old before weaning.  Tail snips 
were incubated with DNA extraction buffer (100 mM Tris pH8.0, 0.2% SDS, 5 
mM EDTA, and 200 mM NaCl) containing 0.5 mg/mL Proteinase K overnight 
(>16 hours) at 55oC.  To extract the DNA samples were incubated 30 minutes at 
room temperature with Phenol/chloroform.  After centrifugation the soluble 
fraction was transferred to a new tube and DNA was precipitated with 100% 
Ethanol.  DNA was washed with 70% ethanol and finally dissolved in 
distilled/deionized autoclaved water.   
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 Mouse tales DNA were used to perform polymerase chain reaction (PCR) 
for Leptin receptor.  Primer sequences: 5' AGA ACG GAC ACT CTT TGA AGT 
CTC 3' and 5' CAT TCA AAC CAT AGT TTA GGT TTG TGT 3' (Jackson 
Labotratories, Bar Harbor, Maine) Tm 52oC. PCR products were digested with 
Rsa I restriction enzyme, Rsa I recognize the leptin receptor point mutation (Fig. 
2.10).  2% low-melting agarose gel was used to separate the bands to identify 
wild-type, heterozygous and homozygous leptin receptor mice.   
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Figure 2.10.3: Genotyping for Lepr PCR products digested with RsaI 
restriction enzyme.  2% low melting agarose gel was used for detection of leptin 
receptor gene single point mutation G to T that results in a stop codon.  Mutant 
leptin receptor was identified by PCR product digestion with the RsaI restriction 
enzyme.  Heterozygous female and male Leprdb/db mice show a 135 bp band 
(wild type) and a 108 bp band (mutant).  Wild type mice only show the 135 bp 
band. Homozygous for the leptin receptor mutation show only a band at 108 bp 
(data not shown).  Mutant males show a nonspecific band above the 135 bp as 
described by Jackson Laboratories.  
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2.11 Pancreatic Cancer Orthotopic Syngeneic Mouse Model 
 Mouse treatment with metformin started two weeks prior to the surgery.  
Metformin was provided by oral gavage at increasing doses starting at 50 
mg/Kg/day until reach to 300 mg/Kg/day for Leprdb/Leprdb and 300 mg/Kg/day for 
Ay/a mice.  The Mice were prepared for surgery by shaving the left side of their 
bodies prior to the surgery. Isofluorane (Fisher, Pittsburg, PA) was used to 
anesthetize the mice to perform the surgery.  PancO2 cells were prepared 
200,000 cells in 30 µL Matrigel with reduced growth hormones (BD Bioscience, 
San Jose, CA) and injected into the pancreas of the mice (Fig 2.11).  
  
	   	  33	  
 
 
 
 
 
Figure 2.11: Surgical procedure for PancO2 orthotopic syngeneic mouse 
model.  Mice were anesthesized using isofluorane (A), an incision was 
performed in the left side of the mouse (B) to expose the pancreas for injection of 
2 x 105 PancO2 cells with matrigel containing low growth factors in 30 µL total 
volume (C-D).  Pancreas was returned into the abdominal cavity and the wound 
was sutured (E).  Mice were observed for recovery.  
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2.12 Oral Glucose Tolerance Test (OGTT)  
 Mouse glycemic status was established by oral glucose tolerance test 
(OGTT) (Zhao et al., 2011).   Mice were fasting for 16 hours previous to the 
OGTT and blood glucose was measured previous to the glucose oral gavage 
(1.5 g/Kg) and measured at 15, 30, 60, and 120 minutes after.  Plot for the 
glucose levels against time and the area of the curve were performed.  
 
2.13 In vivo imaging  
Tumor growth were monitored using Xenogen IVIS 100 (Perkin Elmer, 
Waltham, MA).  150 mg/Kg D-luciferin (Perkin Elmer, Waltham, MA) were i.p. 
injected into each mouse prior to the imaging.  Images were captured 5, 10 and 
15 minutes after D-luciferin injection.   
 
2.14 Transcriptomic analysis 
 A portion of the orthotopic syngeneic pancreatic cancer tumors obtained at 
the end point was used for total RNA extraction with TRIzol (Life Science 
Technologies, Grand Island, NY).  Gene expression analyses of the RNA 
samples were performed at the Genomic Core Facility at The University of Texas 
M. D. Anderson Cancer Center.  Illumina MouseWG-6_V2_0_R3 (Illumina Inc, 
Madison, WI) array platform was used to examine the transcriptomic profile of the 
allografted PancO2 pancreatic tumor samples. 
 Data obtained from the gene array was analyzed using Nexus Expression 
Analysis (BioDiscovery Inc., Hawthorne, CA). Those genes that were found to 
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have significant difference (p<0.01) were further analyzed.  Genes with changed 
expression that was significant (P≤0.01, absolute value of log ratio >0.1, pool 
size for intensity-based pooling 100,000) are presented as heat maps and also 
are listed in Tables.   
 
2.15 Metabolic analysis 
  Pancreatic tumors were collected from mice and 100 µg were snap frozen 
for metabolomic analyses (Metabolon, Durham, NC).  Eight samples of each 
group: control (lean), obese (Ay/a mouse), diabetic (Leprdb/Leprdb), Ay/a treated 
with metformin, and Leprdb/Leprdb treated with metformin. Samples were 
processed for Metabolon standard solvent extraction method.  Then, samples 
were divided in two parts for Gas chromatography/ Mass Spectrometry (GC/MS) 
and liquid chromatography/MS/MS  (LC/MS/MS).  For pair-wise test Welch’s t-
test and/or Wilcoxon’s rank sum test were used. For repeated measures Anova 
analysis was used. For classification random forest analysis was performed. 
Statistical analyses were performed with the program “R” http://cran.r-
project.org/.    
 
2.16 Multiplex analysis 
 Protein samples from allografted PancO2 tumors were used for multiplex 
immuno-analysis (EMD Millipopre, Billerica, MA) to study the AKT/mTOR 
pathway.  Total and phosphorylated proteins were analyzed.   
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Multiplex consist on the use of a unique combination of magnetic 
microsphere covalently coupled to the antibody to capture the protein of interest.  
A second biotinylated labeled antibody that detect the protein of interest in a 
secondary site to make an immuno-sandwich.  These combinations of dyes 
generate a unique fluorescent signature for each bead set.   Multiplex is 
performed in 96-well plates using approximately 20 µg of protein per kit to detect 
several target proteins in each sample.  Magnetic beads are maintained in the 
bottom of the plate using a magnet for at least 1 minute before changing the 
different buffers and solutions. Streptavidin-Phycoerythrin (SA-PE) was used for 
detection.  Luminex 200 system (Luminex Corporation, Austin, TX) was used to 
analyze the samples.  
 
2.17 Statistical analysis 
Sigma plot, software (Systat Inc., San Jose, CA) or GraphPad Prism 
version 6 were utilized to perform statistical analyses.  Different tests were used 
along this project according to the experimental design.  Student t-test or one-
way Anova were used to establish statistical differences.  Statistical difference 
was considered if p≤ 0.05.  
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Chapter 3. Results 
3.1 Studying the role of glucose, insulin and adipocytes on pancreatic 
cancer and the effect of anti-diabetic drugs. 
3.1.1 Glucose, insulin and adipocytes cause cancer cell growth and 
metabolic changes 
 High levels of glucose, high adipocyte content and insulin are some of the 
characteristics of DM2.  Therefore we study the effect of glucose, insulin and 
adipocytes on pancreatic cancer cell growth.   
 Pancreatic cancer cells Panc-1 and MIA PaCa-2 were initially plated at 
equal number with different concentrations of insulin and glucose and cultured for 
72 hours.  Live cells were measured by MTT assay measuring the optical density 
(O.D. at 570 nm) (Figure 3.1.1-1).  Insulin promotes cell proliferation.  Glucose 
effect on promoting cancer cell growth was markedly higher at low 
concentrations of insulin.  This phenomenon was also observed in breast cancer 
cells (Figure A1).  
To study the effect of adipocytes on pancreatic cancer cell growth we 
used differentiated 3T3-L1 in co-culture.  PancO2 mouse pancreatic cancer cell 
line was culture with pre-adipocytes and adipocytes.  After 72 hours of co-culture, 
we found that adipocytes promote the proliferation of PancO2 cells (Figure 3.1.1-
2).  
MTT assays to compare proliferation between treatments with different 
conditioned media, mimicking physiological normal, diabetes, obese, and 
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diabetes/obesity situations (Figure 3.1.1-3).  Different condition media were 
prepared with varied concentrations of glucose, insulin and leptin levels as 
described in Table 2.2.3, Materials and Methods section.  Diabetes, obesity, and 
DM2/obese conditioning media promoted the cell proliferation compared with 
control. 
Oxygen consumption rate (OCR) in MIA PaCa-2 cells is reduced by co-
culture with adipocytes.  Moreover, OCR/Extracellular acidification rate 
(OCR/ECAR) ratio is also decreased by co-culture with adipocytes (Figure 3.1.1-
4).  
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Figure 3.1.1-1. Pancreatic cancer cells proliferation is accelerated by 
glucose and insulin.  MTT assays to determine the proliferation of Panc-1 (left) 
and MIA PaCa-2 (right), upon stimulation with different concentrations of insulin 
and glucose.  Different concentrations of insulin (0, 0.0005, 0.5 and 5 µg/L: x-
axis) and glucose (500, 1,000, 2,000 and 4,000 mg/L: z-axis).  O.D. 570 was 
used to measure cell proliferation (y-axis).  Reprinted with permission from Wiley 
Online: Journal of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et 
al., 2011), copyright 2011.  
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Figure 3.1.1-2: Co-culture of 3T3-L1 adipocytes promotes PancO2 cell 
growth.  3T3-L1 were cultured and differentiated to adipocytes in the Boyden 
chamber wells.  PancO2 cells were seeded in the membrane and co-culture with 
either pre-adipocytes or mature adipocytes for 72 hours.  PancO2, pre-adipocyte 
and adipocyte cells were tripsinized and counted.  Adipocytes were used to 
normalize based on the cell number.  One-way Anova statistical analysis was 
used. Error bars represent 95% confidence. 
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Figure 3.1.1-3: Diabetes mellitus type 2 (DM2), Obese and DM2/Obese 
media enhance pancreatic cancer cells proliferation.  MIA PaCa-2 cells were 
cultured for 72 hours in different condition media for DM2, obese and DM2/obese 
media.  One-way ANOVA statistical analysis shows significant differences 
between normal condition media and all the conditions DM2, Obese and diabetic 
of p<0.001. 
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Figure 3.1.1-4: Adipocytes promote a shift in the glucose metabolism 
toward aerobic glycolysis in pancreatic cancer cells. Oxygen Consumption 
Rate/Extracellular Acidification Rate ratios of MiaPaCa2 cells (cultured alone or 
co-cultured with pre-adipocytes or adipocytes) were determined at baseline and 
upon sequential injection of Oligomycin, FCCP and Rotenone + Antimycin A. 
Each treatment was repeated in 4 independent wells of XF96 microplate.  	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3.1.2 Metformin and Rosiglitazone reduce cancer cells growth in vitro.  
We have established the important role of diabetes and obesity in 
pancreatic cancer cell growth, therefore we hypothesize that controlling glucose 
levels may be beneficial.  MIA PaCa-2 cells were cultured with different anti-
diabetic treatments (metformin, rosiglitazone and exenatide) and the anti-obesity 
treatment orlistat.   Result shows that metformin, rosiglitazone and orlistat 
decrease the pancreatic cancer cell proliferation (Figure 3.1.2-1) under different 
condition media: normal (Figure 3.1.2-1A), obese (Figure 3.1.2-1B), DM2 (Figure 
3.1.2-1C) and DM2/obese (Figure 3.1.2-1D).  Metformin did not have much effect 
under normal condition media (Figure 3.1.2-1A) but it decreases proliferation 
when cells are in obese (Figure 3.1.2-1B), DM2 (Figure 3.1.2-1C) and 
DM2/obese (Figure 3.1.2-1D) media.   Rosiglitazone and orlistat treatments were 
effective under all the conditions (Figure 3.1.2-1A-D).  Excenatide did not have 
any effect on proliferation, probably due to its mechanism of action. 
To further study the effect of metformin and rosiglitazone on proliferation 
the number of viable cells after treatment was determine by cell counting.  Both 
treatments show statistical significant effect decreasing proliferation of MIA 
PaCa-2 cells when compare with the control (Figure 3.1.2-2). 
To study the effect of metformin on adipocytes-induced pancreatic cancer 
cell proliferation we used the in vitro co-culture system to grow PancO2 cells with 
3T3-L1 differentiated adipocytes.  After 72 hours of treatment with metformin, our 
results showed that metformin decreases adipocytes-induced pancreatic cancer 
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cell proliferation significantly at concentrations of 0.5 mM and 1 mM (Figure 
3.1.2-3).   
Since we have found that metformin and rosiglitazone can reduce 
proliferation of pancreatic cancer cells we investigated if these treatments affect 
cell migration by doing wound-healing assay.  Cell images were captured for 36 
hours while incubated with treatments. Wound gap was almost completely closed 
after 36 hours for Control (Figure 3.1.2-4 A left column) while the wounds of cells 
with metformin and rosiglitazone treatments remain open (Figure 3.1.2-4 A 
center and right column). Wound area was measured and plotted (Figure 3.1.2-4 
B) showing that both treatments prevent the wound closure indicative of a 
reduction in cell migration.  In addition we tested metformin and rosiglitazone 
effect on migration of breast (Her 18, Figure A.2) and ovarian (ES-2, Figure A.3) 
cancer cell lines, where we observed similar results. 
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Figure 3.1.2-1: MIA PaCa-2 proliferation is reduced by Metformin, 
Rosiglitazone and Orlistat treatments.  MIA PaCa-2 cells control or treated 
with Metformin (20 mM), Rosiglitazone (100 µM), Orlistat (10 mM), and 
Excenatide (250 µg/mL). Cells were cultured for 48 hours with the treatments in 
different conditioning media normal (A), obese (B), DM2 (C) or DM2/Obese (D).  
MTT assay were performed and plotted. Error bars are 95% confidence intervals. 
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Figure 3.1.2-2: Rosiglitazone and Metformin treatments reduce MIA PaCa-2 
cell growth. Trypan blue staining was used to determine the effect of Metformin 
and Rosiglitazone on MIA PaCa-2 cells proliferation.  Cells were culture 24 hours 
with no drug (control), 100 µM Rosiglitazone or 20 mM Metformin.  Results show 
statistical significant difference between the groups tested by One-way ANOVA.  
Error bars are 95% confidence. 
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular 
Medicine (Feng, Velazquez-Torres et al., 2011), copyright 2011.  
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Figure 3.1.2-3: Metformin reduced proliferation of PancO2 co-cultured with 
3T3-L1 adipocytes.  Boyden chamber co-culture system (0.4 µm membrane) 
was used to determine the effect of Metformin in PancO2 proliferation when co-
culture with 3T3-L1.  Equal number of PancO2 cells were co-culture with 
differentiated 3T3-L1 adipocytes with Control (no treatment), 0.1 mM Metformin, 
0.5 mM Metformin, and 1 mM Metformin for 72 hours.  The graph shows the 
proliferation of PancO2 cells normalized with the number of adipocytes.  One-
way ANOVA statistic analysis was used to compare the groups.  Error bars 
represent 95% confidence.  
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Figure 3.1.2-4: Metformin and Rosiglitazone inhibit migration of MIA PaCa-2 
cells. MIA PaCa-2 cells were plated and incubated to form a monolayer.  Then, a 
wound (scratch) was performed and treatments were added.  (A) Wound closure 
was monitored by using time-lapse microscopy and images of MiaPaCa-2 cells 
show the wound area over at different time points 0, 12, 24, and 36 hours.   
(B) Plot of the quantitated wound area at different time points.  Each treatment 
was normalized with its time 0 hours (initial wound area). 
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3.1.3 Metformin and Rosiglitazone Promote Apoptosis of Pancreatic 
Cancer Cells 
To study deeper the mechanism by which Metformin and Rosiglitazone 
prevent pancreatic cancer cell proliferation and migration we analyze the drugs 
effect on apoptosis.  Indeed Metformin and Rosiglitazone increased cell 
apoptosis analyzed using flow cytometry analysis for FITC-Annexin-V staining 
(Figure 3.1.3-1).  Results from flow cytometry analysis after PI staining of 
PancO2 cells treated with Metformin or Pioglitazone (another type of 
thiazolidinedione drug) show that SubG1 population is increased after treatment 
(Table 3.1.3).  
 Western Blot analysis to detect apoptotic markers confirmed that 
apoptosis treatement with metformin and rosiglitazone are causing apoptosis to 
pancreatic cancer cells.  PTEN tumor suppressor gene increases with 
rosiglitazone and also decreases AKT (Ser473) phosphorylation (Figure 3.1.3-2).  
Both metformin and rosiglitazone inhibit anti-apoptotic protein Bcl-2 and promote 
PARP cleavage (85 KDa band) (Figure 3.1.3-2).  Metformin cause 
phosphorylation of AMPK (Thr172).  To study the regulation of mTOR pathway 
by these drugs we perform Western Blot analysis to determine phosphorylation 
of mTOR and some of its downstream targets.  Results showed that both drugs 
decreased phosphorylation of mTOR (Ser2448) and its downstream target pS6 
Ribosomal protein (Ser235/236) (Figure 3.1.2-3).   For metformin we observed 
that it also caused a decrease in the phosphorylation of p70S6 kinase (Thr 389) 
and 4EBP1 (Ser65) (Figure 3.1.2-3).  These results prove that metformin or 
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rosiglitazone are causing cells death via apoptosis and regulate AKT/mTOR 
signaling. 
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Figure 3.1.3-1: Metformin and rosiglitazone induce apoptosis.  MIA PaCa-2 cells 
were treated with metformin (10 mM) or rosiglitazone (100 µM) for 48 hours.  Cells 
positive for FITC-Annexin-V were detected by flow cytometry analysis, (two right 
quadrants of each graph) early and late apoptosis (also positive for PI staining). Reprinted 
with permission from Wiley Online: Journal of Cellular and Molecular Medicine (Feng, 
Velazquez-Torres, et al.2011), copyright 2011. 
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Table 3.1.3: Metformin and Pioglitazone treatments increased PancO2 Sub 
G1 population.  
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Figure 3.1.3-2: Regulation of apoptotic proteins by rosiglitazone and 
metformin treatments favoring cell death.  Western Blots of MIA PaCa-2 cells 
total protein extracts for PTEN, phospho-AKT (Ser 473), phospho-AMPK 
(Thr172) and Bcl-2 all obtained from Cell Signaling Technologies (Danvers, MA), 
PARP (BD Bioscience, San Jose, CA) and Tubulin (Sigma, Saint Louis, MO). 
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular 
Medicine (Feng, Velazquez-Torres et al. 2011), copyright 2011. 
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Figure 3.1.3-3: Inhibition of mTOR pathway by metformin and rosiglitazone 
on pancreatic cancer cells. MIA PaCa-2 cells were treated with Metformin 
(20mM) or Rosiglitazone (100 µM) for 48 hours.  Western Blot analysis for total 
mTOR (Novus Biologicals, Littleton, CO), phospho-mTOR, p70S6 Kinase, pS6 
Ribosomal Protein, S6 ribosomal protein, phospho-4EBP1, and 4EBP1 (Cell 
Signaling Technologies, Danvers, MA) and Tubulin (Sigma, Saint Louis, MO).  
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular 
Medicine (Feng, Velazquez-Torres, et al. 2011), copyright 2011. 
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3.1.4 Anti-diabetic drugs shift pancreatic cancer cells glucose uptake 
and metabolic state 
To test the effect of the anti-diabetic drugs (metformin and rosiglitazone) and 
the anti-obesity drug (orlistat) on glucose uptake, 2-NBDG, a fluorescent glucose 
analog (Life Science Technologies, Grand Island, NY), was used.  Cells that had 
glucose uptake were seen fluorescent (Figure 3.1.4-1, Top panel).  In addition, 
flow cytometry analysis was performed to quantitate the number of cells positive 
for 2-NBDG (Figure 3.1.4-1, bottom panel).  All the treatments showed decrease 
glucose uptake when compare with control, non-treated, cells.   
 We proceed to measure the basal extracellular acidification rate (ECAR) in 
cells treated with metformin, to understand the glycolytic flux.  ECAR was less in 
the metformin treated at 2.5 mM and 5.0 mM (Figure 3.1.4-2 top panel).  In 
addition to the ECAR we measure the basal oxygen consumption rate (OCR), 
indicative of mitochondrial respiration, which was lower in the metformin treated 
cells (Figure 3.1.4-2 bottom panel). 
 
 
 
  
	   	  56	  
 
 
 
Figure 3.1.4-1: Metformin, rosiglitazone and orlistat reduce glucose uptake 
in pancreatic cancer cells.  Representative Fluorescent images of MIA PaCa-2 
cells taken at 0, 1 and 2 hours of 2-NBDG incubation for control or treatments, 
metformin, rosiglitazone, metformin/rosiglitazone, orlistat, orlistat/metformin (top 
panel).  Flow cytometry analysis showing 2-NBDG uptake (bottom panel). 
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Figure 3.1.4-2: Metformin shift the glycolytic flux and mitochondrial 
respiration of MIA PaCa-2 cells.  2.5 and 5 mM Metformin shift the extracellular 
acidification rate (ECAR) (top panel) and the oxygen consumption rate (OCR) 
(bottom panel). 
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3.1.5 Metformin and rosiglitazone decrease pancreatic cancer tumor growth 
in an in vivo xenograft mouse model  
 To test the potential of metformin and rosiglitazone to inhibit the growth of 
pancreatic cancer in vivo, nude mice xenograft mouse model was used.  Mice 
were subcutaneously injected with MIA PaCa-2 cells in the flanks.  Metformin or 
rosiglitazone treatments were provided into drinking water starting the day of the 
injection.  Twenty five days after injection mice were sacrificed by CO2 
asphyxiation followed by cervical dislocation.   
 Representative mice and tumors from control, rosiglitazone and metformin 
treatment are shown in Figure 3.1.4-1 panel A.  Mice tumors were excised and 
weighed.  Tumor weight was plot against each treatment (Figure 3.1.4-1B). 
Rosiglitazone and Metformin both show a decrease in the tumor weight but 
metformin was the one with the largest change.  Also metformin staining of Ki-67 
shows a decrease in staining when compare for control (Figure 3.1.4-2 top row).  
There was no difference in the caspase-3 staining between the groups (Figure 
3.1.4-2 bottom row). 
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Figure 3.1.5-1: Tumor mass in MIA PaCa-2 cell is decreased with 
rosiglitazone and metformin treatments.  (A) Representative mice from 
control, rosiglitazone treated, metformin treated (top panel) and their resected 
tumors (bottom panel).  (B) Tumor mass were plotted for each treatment, each 
group n=5.  Error bars represent 95% confidence. 
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Figure 3.1.5-2: Immunohistochemistry (IHC) analysis of MIA PaCa-2 tumor 
xenograft.   
Tumors from MIA PaCa-2 cells xenograft were analyzed by IHC. Ki-67 and 
caspase-3 staining. 
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3.2 Study of the role of obesity and diabetes in pancreatic cancer  
3.2.1 Orthotopic syngeneic mouse models to study in vivo obesity and 
diabetes effects on pancreatic cancer 
In order to further understand the impact of obesity and DM2 in pancreatic 
cancer we employed both obese and diabetic orthotopic/syngeneic allograft 
mouse models. Oral glucose tolerance test was performed to characterize the 
glucose tolerance status on each mouse model (Figure 3.2.1-1A and 3.2.1-2A).  
Our obese mouse model phenocopy the human mild glucose intolerance caused 
by obesity, while our diabetic mouse model shows severe glucose intolerance 
(Figure 3.2.1-1B and 3.2.1-2B). Our observations show that these effects on 
glucose tolerance were suppressed by two-weeks treatment with metformin 
(300mg/Kg/day) Ay/a (Figure 3.2.1-1).  We used in vivo tumor bioluminescence 
imaging from allografted PancO2-Luc-FG12 to access the effect of obesity and 
DM2 on pancreatic tumor growth.  Weekly bioluminescence imaging of the mice 
were performed to monitor tumor growth.  Our results show that in both obese 
(Ay/a) and diabetic (Leprdb/db) allografted-tumor growth is significantly accelerated 
(Figure 3.2.1-3 and 3.2.1-4).  Whereas, treatment with metformin decreases 
pancreatic tumor growth in both mouse models (Figure 3.2.1-3 and 3.2.1-4).  
Measurements of allografted tumor weight confirm our in vivo imaging findings 
(Figure 3.2.1-3C).  Comparison of tumors weigh showed significant increase in 
tumor weigh of the non-treated obese mice when compare with the wild type 
mice and a significant reduction in tumor weight was found when compare with 
the obese metformin treated.  Protein and phospho-protein levels analyses of 
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allografted revealed that both obesity and obesity/DM2 in vivo environment 
induce activation of AKT/mTOR signaling pathway protein members (Figure 
3.2.1-5A and 3.2.1-6A). We found that treatment with metformin can revert this 
effect (Figure 3.2.1-5B and 3.2.1-6B). 
Transcriptomic analysis of the allografted pancreatic cancer tumors 
showed that tumors from obese mice had significantly increased expression of 
342 genes and significantly decreased expression of 568 genes compared with 
those from lean littermate mice (Figure 3.2.1-7). Allografted pancreatic cancer 
tumors from diabetic mice had significantly increased expression of 2078 genes 
and significantly decreased expression of 3937 genes compared with those from 
non-diabetic lean littermate mice (Figure 3.2.1-9).  Metformin treatment showed 
that tumors from treated obese mice had significantly increased expression of 
157 genes and significantly decreased expression of 282 genes compared with 
those from non-treated obese mice (Figure 3.2.1-7).  Metformin-treated diabetic 
mice had significantly increased expression of 218 genes and significantly 
decreased expression of 172 genes compared with those from non-treated 
diabetic mice (Figure 3.2.1-9).   
We used Nexus Expression 3 software to perform unsupervised functional 
transcriptomic analysis. This analysis identified 29 biological processes that were 
significantly different (P<0.01) between the obese and non-obese mice (Table 
3.2.1-1), and 17 biological processes between the obese /DM2 and non-diabetic 
mice (Table 3.2.1-3). We also identified 30 biological processes that were 
significantly different (P<0.01) between the metformin-treated obese and non-
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treated obese mice (Table 3.2.1-2), and 76 biological processes between the 
metformin-treated diabetic and non-treated diabetic mice (Table 3.2.1-4).  Using 
gene set enrichment analysis (GSEA) (Subramanian et al., 2005), which is 
considered more supervised and specific transcriptomic analysis, we showed 
significant upregulation of protein kinase B (AKT) target genes, genes involve in 
the glucose metabolism, and genes involve in the epithelial-mesenchymal 
transition (EMT) in allografted pancreatic tumors from both mouse models 
(Figure 3.2.1-8 and figure 3.2.1-10). Thus, our data suggests that obesity and 
obesity/diabetic in vivo environment promote tumor growth and aggressiveness 
via the AKT/mTOR signaling pathway and by promoting transcriptional changes 
enhancing glucose metabolism and a more invasive phenotype. 
 In order to investigate the metabolomic changes induced by obesity and 
diabetes, we sent the allografted pancreatic tumor samples for metabolomic 
analysis.  Global biochemical profiling of allografted tumor tissues revealed a 
large number of differences that were observed in both obese and diabetic 
mouse models, as compared to control littermates.  Metabolomic results showed 
113 metabolites that were significantly different (P<0.05) between the obese and 
non-obese mice, and 117 metabolites significantly different between the obese 
/DM2 and non-diabetic mice (Figure 3.2.1-11 and Figure 3.2.1-12).  Most of 
these differences are associated with lipid metabolism, amino acids, dipeptides, 
nucleotides metabolism and oxidative stress. 
Levels of long chain free fatty acids (FFA), including the essential fatty 
acids linoleate and linolenate, were significantly elevated in allografted tumors 
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from both obese and diabetic mouse models, relative to control littermates.  In 
addition to FFA, monoacylglycerols were increased significantly in tumors from 
obese mice. Moreover, tumors from obese mice showed significant increase in 3-
hydroxybutryate (BHBA) and trending increases in acetyl-carnitine. In addition to 
changes in lipid metabolism, glucose and fructose levels were elevated in tumors 
from diabetic mice. Tumors from both obese and diabetic mice showed 
significantly low levels of glucose-6-phosphate and fructose-6-phosphate, while 
3-phosphoglycerate and phosphoenolpyruvate (PEP) were elevated with no 
difference in lactate levels in comparison to control littermates. Metformin 
treatment slightly increased in glucose-6-phosphate, fructose-6-phosphate, and 
PEP, while significantly increased levels of several sugar alcohols (e.g., galactitol 
and xylitol), N-acetylneuraminate, and mannose-6-phosphate in tumor from from 
both obese and diabetic mice. 
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Figure 3.2.1-1: Metformin decreases obesity-induced mild glucose 
intolerance in obese orthotopic/syngeneic pancreatic cancer mouse model.  
(A) Oral glucose tolerance tests (OGTT) of obese (B6;Ay/a, n=12) and lean 
(B6;a/a, n=9) littermate mice. Error bars represent 95% confidence intervals.  
(B) Oral glucose tolerance tests (OGTT) of obese (B6;Ay/a, n=11) and metformin-
treated (300mg/Kg/day) obese (B6;Ay/a - Metformin, n=9) after two weeks of 
treatment. Error bars represent 95% confidence intervals. 
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Figure 3.2.1-2: Metformin decreases diabetes-induced glucose intolerance 
in diabetic orthotopic/syngeneic pancreatic cancer mouse model. (A) Oral 
glucose tolerance tests (OGTT) of diabetic (B6;Leprdb/db, n=10) and lean 
(B6;Lepr+/+, n=4) littermate mice. Error bars represent 95% confidence intervals. 
(B) Oral glucose tolerance tests (OGTT) of diabetic (B6;Leprdb/db, n=4) and 
metformin-treated (300mg/Kg/day) diabetic mice (B6;Leprdb/db - Metformin, n=4) 
after two weeks of treatment. Error bars represent 95% confidence intervals. 
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Figure 3.2.1-3: Metformin decreases obesity-induced orthotopic/syngeneic 
pancreatic tumor allograft growth. (A) Bar graph of the relative 
bioluminescence intensity generated by the tumor of randomized B6;a/a (lean, 
n=13), B6;Ay/a (obese, n=13), and metformin-treated obese (n=8) mice injected 
into the pancreas body with pancreatic cancer after two week of treatment. (B) 
Representative in vivo imagings of tumors’ bioluminescence performed 3-week 
after orthotopic/syngeneic injection. (C) Representative images of syngeneic 
allografted tumors harvested from randomized lean, obese, and metformin-
treated obese female mice (left panel, scale bars represent 5 mm). A bar graph 
illustrates the mean tumor weights (right panel; n≥5 mice per group). Error bars 
in panels A and C represent 95% confidence intervals. 
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Figure 3.2.1-4: Metformin decreases diabetes-induced orthotopic/syngeneic 
pancreatic tumor allograft growth. (A) Bar graph of the relative 
bioluminescence intensity generated by the tumor of randomized B6;Lepr+/+ 
(lean, n=6), B6;Leprdb/db (diabetic, n=5), and metformin-treated B6;Leprdb/db (n=5) 
mice injected into the pancreas body with pancreatic cancer after two week of 
treatment. Error bars represent 95% confidence intervals. (B) Representative in 
vivo imaging of tumors’ bioluminescence performed 3-week after 
orthotopic/syngeneic injection.  
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Figure 3.2.1-5: Metformin decreases obesity-induced activation of 
AKT/mTOR signaling pathway in orthotopic/syngeneic pancreatic tumor 
allografts. 
(A) Phospho-protein levels of members of the Akt/mTOR signaling pathway from 
syngeneic allografted tumor lysates from obese (B6;Ay/a, n=4) mice plotted 
relative to those from lean mice (B6;a/a, n=4). (B) Phospho-protein levels of 
members of the AKT/mTOR signaling pathway from syngeneic allografted tumor 
lysates from metformin-treated obese mice (B6;Ay/a - Metformin, n=4) plotted 
relative to those from obese mice (B6;Ay/a, n=4). Error bars represent 95% 
confidence intervals. 
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Figure 3.2.1-6: Metformin decreases diabetes-induced activation of 
AKT/mTOR signaling pathway in orthotopic/syngeneic pancreatic tumor 
allografts. 
(A) Phospho-protein levels of members of the Akt/mTOR signaling pathway from 
syngeneic allografted tumor lysates from diabetic (B6;Leprdb/db, n=4) mice plotted 
relative to those from non-diabetic lean mice (B6;Lepr+/+, n=4). (B) Phospho-
protein levels of members of the AKT/mTOR signaling pathway from syngeneic 
allografted tumor lysates from metformin-treated diabetic mice (B6;Leprdb/db - 
Metformin, n=4) plotted relative to those from diabetic mice (B6;Leprdb/db, n=4). 
Error bars represent 95% confidence intervals. 
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Figure 3.2.1-7 
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Figure 3.2.1-7: Transcriptomic changes associated with obesity and 
metformin treatment in orthotopic/syngeneic pancreatic tumor allografts. 
Heat map of the gene-probes significantly changed (p≤0.01, absolute value of log 
ratio >0.1, pool size for intensity-based pooling 100,000; identified by Nexus 
Expression software) in pancreatic tumor allografts from obese mice (B6;Ay/a, 
n=5) and metformin-treated obese mice (B6;Ay/a - Metformin, n=4) relative to 
those from lean littermate mice (B6;a/a, n=5).  
  
	   	  73	  
Table 3.2.1-1: Biological processes significantly (P<0.05) changed in 
orthotopic/syngeneic pancreatic tumor allografts from obese compared 
with non-obese mice identified by Nexus Expression. 
BIOLOGICAL PROCESS SCORE P-VALUE 
antigen receptor-mediated signaling pathway -1.674291143 0.001937984 
male sex determination -1.589172 0.00204499 
positive regulation of protein kinase activity -1.592165906 0.002079002 
CTP biosynthesis 1.562645101 0.003992016 
GTP biosynthesis 1.562645101 0.003992016 
UTP biosynthesis 1.562645101 0.003992016 
regulation of balance 1.464688487 0.01039501 
regulation of cytokine biosynthesis -1.523279242 0.014084507 
L-phenylalanine catabolism -1.595330852 0.01511879 
zinc ion transport 1.628073818 0.016326531 
protein-chromophore linkage -1.5470298 0.020964361 
positive regulation of B cell differentiation -1.541536515 0.023206751 
purine nucleotide biosynthesis 1.555811852 0.024122807 
negative regulation of translation -1.597175314 0.026156942 
synaptogenesis -1.513086526 0.027659574 
embryonic development 1.42049563 0.029880478 
neurotransmitter secretion -1.406220147 0.030425963 
protein homotetramerization 1.450249763 0.034764826 
response to pheromone -1.375537775 0.034836066 
phospholipid metabolism -1.695367327 0.036363636 
regulation of neuronal synaptic plasticity -1.556929042 0.041666667 
lipid catabolism -1.42955195 0.042471042 
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motor axon guidance 1.495323573 0.042735043 
metabotropic glutamate receptor signaling 
pathway -1.439473425 0.044624746 
protein metabolism 1.472455261 0.047058824 
B cell proliferation -1.525351343 0.047520661 
regulation of embryonic development -1.449610805 0.049079755 
brown fat cell differentiation -1.512420027 0.049462366 
cortical actin cytoskeleton organization and 
biogenesis -1.500347696 0.049689441 
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Table 3.2.1-2: Biological processes significantly (P<0.05) changed in 
orthotopic/syngeneic pancreatic tumor allografts from metformin-treated 
obese compared with obese mice identified by Nexus Expression. 
BIOLOGICAL PROCESS SCORE P-VALUE 
nerve-nerve synaptic transmission -1.888074216 0 
acyl-CoA metabolism -1.83675073 0 
pathogenesis -1.692701962 0 
negative regulation of immune response 1.592019747 0 
determination of adult life span 1.556203985 0.002053388 
retinol metabolism 1.598047026 0.004056795 
apoptotic mitochondrial changes 1.736510417 0.005847953 
peptidyl-tyrosine phosphorylation -1.615307463 0.006 
inactivation of MAPK activity 1.812358097 0.00804829 
protein export from nucleus 1.638087376 0.011235955 
membrane protein ectodomain proteolysis -1.637538491 0.013861386 
negative regulation of endothelial cell 
proliferation 1.535684452 0.013916501 
histidine catabolism -1.508614122 0.02016129 
lysosome organization and biogenesis 1.253259938 0.023404255 
response to stress 1.576056745 0.026915114 
translation 1.591697195 0.027777778 
cell proliferation 1.370079768 0.030674847 
actin filament-based movement 1.470453563 0.030737705 
cell migration -1.639441954 0.031311155 
protein kinase C activation 1.574812075 0.032 
regulation of balance 1.482277402 0.033126294 
monoamine transport -1.510035928 0.036585366 
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response to heat 1.504802915 0.037623762 
amino acid transport -1.57012118 0.037924152 
triacylglycerol metabolism 1.507384466 0.043396226 
isotype switching 1.437620693 0.044921875 
monovalent inorganic cation transport -1.467085774 0.046601942 
release of cytochrome c from mitochondria 1.497734491 0.04743833 
osteoclast differentiation 1.542993892 0.048484848 
positive regulation of axon extension 1.456913489 0.049309665 
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Figure 3.2.1-8: Gene Set Enrichment Analysis of orthotopic/syngeneic 
pancreatic tumor allografts transcriptomic profiles from obese and 
metformin-treated obese mice. 
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Figure 3.2.1-8: Gene Set Enrichment Analysis of orthotopic/syngeneic 
pancreatic tumor allografts transcriptomic profiles from obese and 
metformin-treated obese mice. 
Gene Set Enrichment Analyses (GSEA) of transcriptomic profile from obese mice 
(left panels) and metformin-treated obese mice (right panel) relative to their 
control littermate mice. GSEA were for (A) AKT activation target genes, (B) 
genes involve in the glucose metabolism, and (C) genes involve in the epithelial-
mesenchymal transition (EMT) and metastasis. Each bar corresponds to one 
gene.  
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Figure 3.2.1-9 
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Figure 3.2.1-9: Transcriptomic changes associated with diabetes and 
metformin treatment in orthotopic/syngeneic pancreatic tumor allografts. 
Heat map of the gene-probes significantly changed (p≤0.01, absolute value of log 
ratio >0.1, pool size for intensity-based pooling 100,000; identified by Nexus 
Expression software) in pancreatic tumor allografts from diabetic mice 
(B6;Leprdb/db, n=4) and metformin-treated diabetic mice (B6;Leprdb/db - Metformin, 
n=4) relative to those from non-diabetic lean littermate mice (B6;Lepr+/+, n=5).  
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Table 3.2.1-3: Biological processes significantly (P<0.05) changed in 
orthotopic/syngeneic pancreatic tumor allografts from diabetic mice 
compared with non-diabetic mice identified by Nexus Expression. 
BIOLOGICAL PROCESS SCORE P-VALUE 
actin cytoskeleton organization and biogenesis 1.477698164 0.016483516 
gamma-aminobutyric acid signaling pathway -1.689808152 0.017509728 
cell redox homeostasis 1.498312572 0.017509728 
protein-chromophore linkage -1.543916303 0.01863354 
phosphorylation 1.529232379 0.01875 
tricarboxylic acid cycle 1.570427574 0.018907563 
Mo-molybdopterin cofactor biosynthesis 1.450729032 0.031936128 
ubiquitin-dependent protein catabolism 1.458953173 0.034615385 
purine nucleotide biosynthesis 1.599643861 0.036538462 
proton transport 1.41897114 0.037280702 
axon guidance -1.418488144 0.03815261 
protein homotetramerization 1.382782216 0.040152964 
cell motility 1.521752194 0.042635659 
cobalt ion transport -1.454758732 0.045833333 
ovulation (sensu Mammalia) -1.570571153 0.04743083 
tetrahydrobiopterin biosynthesis 1.523609736 0.048300537 
copper ion transport 1.49906061 0.049212598 
calcium-dependent cell-cell adhesion -1.391442349 0.049242424 
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Table 3.2.1-4: Biological processes significantly (P<0.05) changed in 
orthotopic /syngeneic pancreatic tumor allografts from metformin-treated 
diabetic mice compared with diabetic mice identified by Nexus Expression. 
BIOLOGICAL PROCESS SCORE P-VALUE 
cytoskeleton organization and biogenesis -1.474161038 0.021543986 
microtubule-based movement -1.393981536 0.022556391 
embryonic development (sensu Mammalia) -1.370492704 0.02259887 
negative regulation of protein kinase activity -1.278196419 0.02259887 
actin cytoskeleton organization and 
biogenesis -1.374793819 0.022944551 
innate immune response 1.59139184 0.023076923 
nitrogen compound metabolism -1.577897779 0.023121387 
axon guidance 1.836990889 0.023166023 
fatty acid desaturation -1.682510548 0.023210832 
negative regulation of cell differentiation -1.639949091 0.023210832 
negative regulation of myeloid cell 
differentiation -1.454776683 0.023255814 
cell glucose homeostasis 2.028564801 0.023300971 
protein polymerization -1.683135887 0.023300971 
transcription initiation 1.432132918 0.023300971 
negative regulation of fibroblast proliferation -1.429501064 0.023575639 
regulation of cholesterol absorption -1.176428311 0.023668639 
natural killer cell differentiation -1.628094531 0.023715415 
regulation of cytokine biosynthesis -1.524173487 0.023762376 
ovulation (sensu Mammalia) 1.643051453 0.023904382 
embryonic pattern specification -1.648132032 0.023952096 
fatty acid metabolism -1.378046378 0.024 
T cell receptor signaling pathway 1.840245041 0.024048096 
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proteoglycan biosynthesis -1.409921279 0.024096386 
embryonic limb morphogenesis -1.777445325 0.024144869 
mitotic chromosome condensation -1.441479318 0.024144869 
melanocyte differentiation -1.568416412 0.024291498 
excretion 1.479631366 0.024439919 
embryonic cleavage 1.590083363 0.024489796 
frizzled-2 signaling pathway -1.632673267 0.024539877 
urogenital system development -1.608792927 0.024590164 
positive regulation of progression through 
mitotic cell cycle -1.582991585 0.024590164 
calcium-independent cell-cell adhesion -1.480983697 0.024691358 
N-acetylglucosamine metabolism 1.603911761 0.024742268 
one-carbon compound metabolism -1.478395123 0.025052192 
defense response 1.549819808 0.025477707 
cartilage condensation -1.474291437 0.025586354 
retrograde axon cargo transport 1.505437065 0.025641026 
immune response 1.644866022 0.026548673 
inner ear morphogenesis 1.393060666 0.035643564 
sulfate transport 1.595707293 0.04494382 
melanin biosynthesis from tyrosine 1.559171666 0.045634921 
lipid metabolism -1.35343213 0.046678636 
sexual reproduction 1.36838016 0.047244094 
MAPKKK cascade -1.270455816 0.048689139 
nerve growth factor receptor signaling 
pathway -1.490130948 0.048828125 
organic anion transport 1.377971903 0.049701789 
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Figure 3.2.1-10: Gene Set Enrichment Analysis of orthotopic/syngeneic 
pancreatic tumor allografts transcriptomic profiles from diabetic and 
metformin-treated diabetic mice. 
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Figure 3.2.1-10: Gene Set Enrichment Analysis of orthotopic/syngeneic 
pancreatic tumor allografts transcriptomic profiles from diabetic and 
metformin-treated diabetic mice. 
Gene Set Enrichment Analyses (GSEA) of transcriptomic profile from diabetic 
mice (left panels) and metformin-treated diabetic mice (right panel) relative to 
their control littermate mice. GSEA were for (A) AKT activation target genes, (B) 
genes involve in the glucose metabolism, and (C) genes involve in the epithelial-
mesenchymal transition (EMT) and metastasis. Each bar corresponds to one 
gene. 
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Figure 3.2.1-11: Metabolomic changes associated with obesity, diabetic and 
metformin treatment in orthtopic/syngeneic pancreatic tumor allografts. 
Heat map of the metabolic molecules (metabolites) significantly changed 
(p≤0.05) in pancreatic tumor allografts from obese mice (B6;Ay/a, n=8) and 
diabetic mice (B6;Leprdb/db, n=8) relative to those from lean littermate mice 
(B6;a/a, n=8), metformin-treated obese mice (B6;Ay/a - Metformin, n=8) relative to 
those from obese mice, and metformin-treated diabetic mice (B6;Leprdb/db - 
Metformin, n=8) relative to those from diabetic mice.  
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Figure 3.2.1-12: Venn diagram of metabolomic profile of pancreatic tumor 
tissue allografts from orthtopic/syngeneic mouse models. 
Venn diagrams of metabolites with significant changed levels from metabolomic 
data. Metabolites with significant changed levels from obese mice and diabetic 
mice relative to those from lean littermate mice (upper panel). Metabolites with 
significant changed levels from obese mice and diabetic mice relative to those 
from lean littermate mice (upper panel) metformin-treated obese mice relative to 
those from obese mice, and metformin-treated diabetic mice relative to those 
from diabetic mice. 
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Chapter 4. Discussion 
Many epidemiological studies have suggested the role of obesity and 
diabetes in pancreatic cancer.  We used a unique strategy to unveil the impact of 
obesity and diabetes on pancreatic cancer growth.  In this work we have in vitro 
and in vivo approaches to better understand the relationship between these three 
conditions.   
 We used different condition media to test different concentrations of 
glucose and insulin in cell culture.  We found that insulin promotes pancreatic 
and breast cancer cells proliferation (Figures 3.1.1-1 and A1).  The results 
indicate that insulin and glucose promote cancer cell growth, but glucose effect is 
insulin-dependent.  Using the in vitro adipocyte system of 3T3-L1 fibroblast 
differentiation, we were able to test the effect of adipocytes on pancreatic cancer 
cell proliferation.  PancO2 cells when co-cultured with adipocytes show a 
significant proliferation (Figure 3.1.1-2).  Moreover, we prepared different 
conditioned media to mimic the diabetes (high glucose and high insulin) and 
obesity (normal glucose, high insulin and high leptin) situations in the body.  We 
were able to observe significant changes between the different conditioned 
media and the normal condition.  This is a simplified conditioned media but we 
were able to detect significant changes in the cell proliferation indicative of the 
importance of glucose, insulin and adipokines in cancer cell growth.  To further 
evaluate the role of adipocytes on the pancreatic cancer cell metabolism we used 
the co-culture system followed by seahorse analysis and found that metformin 
shift the glucose metabolism toward aerobic glycolysis.   
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 As previously described about 80% of the pancreatic cancer patients has 
diabetes (Permert et al., 1993). We have demonstrated that insulin, a basic 
treatment for type 2 diabetes, have proliferative effect on pancreatic and breast 
cancer.  Our hypothesis is that some treatments for DM2 and obesity may have 
beneficial impact in pancreatic cancer. We have found that some anti-diabetic 
treatments, particularly metformin may be beneficial for treatments of pancreatic 
cancer patients with obesity or diabetes.   
Proliferation analyses using different conditioned media (normal, DM2, 
Obese, and DM2/Obese) show that some drug treatments can reduce the cancer 
growth, with only 48 hours cell treatment (Figure 3.1.2-1).  Interestingly, we found 
that metformin, rosiglitazone and orlistat had anti-proliferative effect on cancer 
cell growth.  We did not observe any effect with excenatide treatment, probably 
at a systemic level would have a different outcome.  In fact, we have shown the 
beneficial impact of excenatide to overcome the dexamethasone induced 
glucose intolerance in mice (Zhao et al., 2011).  Metformin has been described to 
be weight neutral or to cause weight-loss (Pi-Sunyer, 2008) so we tested its 
effect when cells are treated in the presence of adipocytes.  Indeed we observe a 
significant decrease in cell proliferation.  To study the impact of metformin and 
rosiglitazone on cell migration we perform wound-healing assay and found that 
these drugs also affect the cell migratory potential (Figures 3.1.2-4, A2 and A3).  
Upon investigating the effect of the anti-diabetic treatments on cancer growth and 
migration we continue studying the apoptotic potential of these drugs.  We 
observed that both metformin and rosiglitazone/pioglitazone were able to double 
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the number of apoptotic cells as seen in the Annexin-V/PI staining and the sub-
G1 population (Figures 3.1.1-1 and Table 3.1.3).  To better understand the 
impact of metformin and rosiglitazone on apoptosis we analyzed the protein 
status of BCL-2 and PARP, apoptosis related proteins.  The levels of cleaved 
PARP were induced by both metformin and rosiglitazone indicative of apoptosis.  
Furthermore the levels of the anti-apoptotic protein BCL-2 were reduced mainly 
in the metformin treatment.  All these findings indicate that metformin and 
thiazolidinediones are capable to reduce cell proliferation and migration partly 
because their ability to induce cell death through apoptosis.   
For additional information on the function of metformin and rosiglitazone in 
inhibiting pancreatic cancer cell proliferation we analyze protein levels of 
AKT/mTOR pathway. Rosiglitazone decreases phosphorylation of AKT (Ser 473) 
(Figure 3.1.3-2), mTOR (Ser 2448), and S6 ribosomal protein (Ser235/236) 
(Figure 3.1.3-3).  Metfomin decreases phosphorylation of mTOR (Ser 2448), S6 
S6 ribosomal protein (Ser235/236), and 4EBP1 (Ser65).  These findings indicate 
that both metformin and rosiglitazone decrease the activity of the AKT/mTOR 
pathway, which is affecting protein synthesis and cell growth.   
 Because glucose promotes the cancer cell proliferation we tested the 
effect of metformin, rosiglitazone and orlistat in glucose uptake and found that all 
of them reduced the glucose uptake in the MIA PaCa-2 cells.  This result could 
be indicative of a switch in metabolism caused by these drugs.  As it has been 
define by Otto Warburg cancer cells relies in glycolysis (Garber, 2006; Yeung et 
al., 2008), and our results indicate that metformin and rosiglitazone are affecting 
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the glucose uptake of the cancer cells.  Also, we tested that metformin had an 
effect on shifting the glycolytic flux and the mitochondrial respiration.   
 In addition to metformin, here we tested other treatments (rosiglitazone, 
orlistat) that seem to have beneficial impact on preventing pancreatic cancer cell 
proliferation.  Although Rosiglitazone has been withdrawn from the market 
because of its cardiotoxic effects, the use of pioglitazone, another 
thiazolidinediones drug may be useful for treatment of diabetes in pancreatic 
cancer patients.  Orlistat was recently approved by FDA (Alli) to use for weight 
loss and based on our in vitro results this may be a promising treatment for 
adjuvant treatment of cancer patients, especially for those obese or diabetes 
patients.  In terms of excenatide we did not observed any effect in the in vitro 
experiments but it is possible that in vivo use will have a different outcome.  
 Thus, metformin and rosiglitazone promoted apoptosis in cancer cells and 
potentiated the apoptotic effect via AMPK and PTEN respectively, both regulating 
the AKT/mTOR signalling pathway.  
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Figure 4-1: Possible mechanisms of action of metformin and rosiglitazone 
in pancreatic cancer cells.  Adapted with permission from Wiley Online: Journal 
of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al., 2011), 
copyright 2011.  
 
 
 
 
	   	  93	  
Our orthotopic/syngeneic in vivo models recapitulates the increased 
caloric intake that eventually promotes the development of obesity and diabetes 
in humans. In this way we were able to study the obesity-related and diabetic-
related biological changes that are promoting pancreatic tumor growth and 
overall pancreatic cancer aggressiveness.  Here we integrated high-throughput 
screening (e.g., transcriptomics and metabolomics), of tumors from our in vivo 
models to determine and validate the biological mechanisms involved in obesity-
accelerated and DM2-accelerated pancreatic cancer.  
The elevated levels of long chain free fatty acids (FFA) in tumors from 
both obese and diabetic mice reflect increased circulating levels of FFA and 
triglycerides as a result of increased food consumption, fatty acid synthesis, and 
mobilization of fat. Concurrent to this increase in FFA, transcriptomic analysis 
showed decrease in genes related to lipid catabolism (e.g., Oc90, Pla2g10) in 
tumors from obese or diabetic mice. Such increases in available fatty acids for 
uptake may provide pancreatic tumors a significant growth advantage as many 
cancers up-regulate fatty acid synthesis to support membrane synthesis (Currie 
et al., 2013). Although Metformin treatment reduced tumor growth in the obese 
and diabetic mice, the levels of FFA in these tumors were not altered in 
comparison to untreated tumors.  Metformin is known to inhibit fatty acid 
synthesis by promoting inhibitory-phosphorylation of acetyl-CoA carboxylase 
(Cantoria et al., 2014). Thus, obesity-induced and DM2-induced increase of FFA 
in tumors is due to an increase in FFA intake by tumor cells.  Fatty acid 
catabolism, however, did appear to be increased in metformin-treated obese 
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mice as indicated by a significant increase in 3-hydroxybutryate (BHBA) levels 
and trending increases in acetylcarnitine, which is an indicator of acetyl-CoA, and 
propionylcarnitine, which are a product of odd-chain fatty acid oxidation as well 
as branched chain amino acid catabolism. Increased β-oxidation in metformin-
treated obese mice is consistent with the activation of AMPK by metformin 
treatment (Pernicova and Korbonits, 2014; Zhou et al., 2001).  These effects 
appeared specific to obese mice.  
Glucose and fructose levels were elevated in tumors from DB mice, 
consistent with hyperglycermia.  In tumors from both obese and diabetic mice, 
the 6-carbon glycolytic intermediates glucose-6-phosphate and fructose-6-
phosphate were significantly lower, while the downstream 3-carbon intermediates 
3-phosphoglycerate and phosphoenolpyruvate (PEP) were elevated, as 
compared to control littermates.  Although lactate levels were not different 
between the groups, these changes are suggestive of decreased utilization of 
glucose in tumors from either obese or diabetic mice coupled with supply of 
downstream glycolytic intermediates from the catabolism of amino acids, such as 
serine and alanine. As a result of some variabilty, several changes were 
observed that were not statistically significant upon comparison tumors from 
metformin-treated and non-treated mice, but yet the observations were 
consistent with Metformin action.  For example, glucose and fructose levels were 
non-significantly reduced in tumors from metformin-treated diabetic mice as 
compared to non-treated diabetic mice.  In addition, a slight increase in glucose-
6-phosphate, fructose-6-phosphate, and PEP were observed in tumors from 
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either obese or diabetic mice, as compared to the appropriate non-treated 
controls.  Together with significantly increased levels of several sugar alcohols 
(e.g., galactitol and xylitol), N-acetylneuraminate, and mannose-6-phosphate in 
tumors from treated obese or diabetic mice, these trends in glycolytic 
intermediates suggest that metformin treatment increased glucose utilization by 
multiple pathways in pancreatic tumors.    
Transcriptomic enrichment analysis showed that tumors from obese or 
diabetic mice have significant induction of expression of many genes related to 
nucleotide biosynthesis. In contrast, the metabolomic analysis showed the purine 
catabolites (e.g., xanthosine, xanthine, and urate) were significantly increased in 
tumors from diabetic mice with metformin treatment.  In tumors from obese mice, 
we found significant and trending increased levels of urate and the pyrimidine 
catabolite β-alanine, respectively, upon comparison of treated tumors to non-
treated tumors.  These changes are indicative of increased nucleic acid turnover 
and production of H2O2 by xanthine oxidase, which may contribute to inhibition of 
tumor growth associated with metformin treatment. 
We have developed a feasible way to study the implications of obesity, 
diabetes, and pancreatic cancer.  Our animal models provide strong evidence for 
the causal relationship between obesity, diabetes and accelerated pancreatic 
cancers.  Using this model we confirm that obesity and diabetes promotes the 
progression of pancreatic cancer and the anti-diabetic drug metformin decreases 
this progression.  This study shed a new insight of the effects of metformin and 
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its potential as part of therapeutic interventions for pancreatic cancer in obese 
and diabetic patients. 
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Chapter 5. Appendix 
Appendix A 
Cancer cell proliferation promoted by insulin and glucose.  
 
 
A.1 Breast cancer cells, MCF7 and Her18, proliferation is accelerated by 
glucose and insulin.  MTT assays to determine the proliferation of MCF7 (left) 
and Her18 upon stimulation with different concentrations of insulin and glucose.  
We used different concentrations of insulin (0, 0.0005, 0.5 and 5 µg/L: x-axis) 
and glucose (500, 1,000, 2,000 and 4,000 mg/L: z-axis).  O.D. 570 was used to 
measure cell proliferation.  Reprinted with permission from Wiley Online: Journal 
of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al., 2011), 
copyright 2011.  
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A.2 Metformin and Rosiglitazone inhibit migration of Her18 cells. A) Time-
lapse images of Her18 cells show the wound area over at different time points 0, 
12, 24, and 36 hours. B) Quantification of the wound area at different time points.  
Each treatment was normalized with its time 0 hours (beginning wound area).   
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A.3 Metformin and Rosiglitazone inhibit migration of ES-2 cells. A) Time-
lapse images of ES-2 cells show the wound area over at different time points 0, 
12, 24, and 36 hours. B) Quantification of the wound area at different time points.  
Each treatment was normalized with its time 0 hours (beginning wound area).
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Figure 3.1.3-1: Metformin and rosiglitazone result in programed cell death, 
apoptosis.  Her18 cells were treated with metformin (10 mM) or rosiglitazone 
(100 µM) for 48 hours.  Cells positive for FITC-Annexin-V were detected by flow 
cytometry analysis, (two right quadrants of each graph) early and late apoptosis 
(also positive for PI staining). Reprinted with permission from Wiley Online: 
Journal of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al.2011), 
copyright 2011. 
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